351 results on '"Anthony C Keech"'
Search Results
2. Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective
- Author
-
Gerald F. Watts, David R. Sullivan, David L. Hare, Karam M. Kostner, Ari E. Horton, Damon A. Bell, Tom Brett, Ronald J. Trent, Nicola K. Poplawski, Andrew C. Martin, Shubha Srinivasan, Robert N. Justo, Clara K. Chow, Jing Pang, Zanfina Ademi, Justin J Ardill, Wendy Barnett, Timothy R Bates, Lawrence J Beilin, Warrick Bishop, J Andrew Black, Alex Brown, John R Burnett, Christina A Bursill, Alison Colley, Peter M Clifton, Elif I Ekinci, Gemma A Figtree, Brett H Forge, Jacquie Garton-Smith, Dorothy F Graham, Ian Hamilton-Craig, Christian R Hamilton-Craig, Clare Heal, Charlotte M Hespe, Amanda J Hooper, Laurence G Howes, Jodie Ingles, Edward D Janus, Nadarajah Kangaharan, Anthony C Keech, Andrew B Kirke, Leonard Kritharides, Campbell V Kyle, Paul Lacaze, Stephen CH Li, Stjepana Maticevic, Brendan M McQuillan, Sam Mirzaee, Trevor A Mori, Allison C Morton, David M Colquhoun, Joanna C Moullin, Paul J Nestel, Kristen J Nowak, Richard C O'Brien, Nicholas Pachter, Michael M Page, Peter J Psaltis, Jan Radford, Nicola J Reid, Elizabeth N Robertson, Jacqueline DM Ryan, Mitchell N Sarkies, Carl J Schultz, Russell S Scott, Christopher Semsarian, Leon A Simons, Catherine Spinks, Andrew M Tonkin, Frank van Bockxmeer, Kathryn E Waddell-Smith, Natalie C Ward, Harvey D White, Andrew M Wilson, Ingrid Winship, Ann Marie Woodward, Stephen J Nicholls, Peter Brett, Luke Elias, Wynand Malan, John Irvin, Kirsten Lambert, and Annette Pedrotti
- Subjects
Familial hypercholesterolaemia ,Guidance ,Care ,Management ,Adults ,Children ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Public aspects of medicine ,RA1-1270 - Abstract
Summary: Introduction: Familial hypercholesterolaemia (FH) is a common, heritable and preventable cause of premature coronary artery disease, with significant potential for positive impact on public health and healthcare savings. New clinical practice recommendations are presented in an abridged guidance to assist practitioners in enhancing the care of all patients with FH. Main recommendations: Core recommendations are made on the detection, diagnosis, assessment and management of adults, children and adolescents with FH. There is a key role for general practitioners (GPs) working in collaboration with specialists with expertise in lipidology. Advice is given on genetic and cholesterol testing and risk notification of biological relatives undergoing cascade testing for FH; all healthcare professionals should develop skills in genomic medicine. Management is under-pinned by the precepts of risk stratification, adherence to healthy lifestyles, treatment of non-cholesterol risk factors, and appropriate use of low-density lipoprotein (LDL)-cholesterol lowering therapies, including statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Recommendations on service design are provided in the full guidance. Potential impact on care of FH: These recommendations need to be utilised using judicious clinical judgement and shared decision making with patients and families. Models of care need to be adapted to both local and regional needs and resources. In Australia new government funded schemes for genetic testing and use of PCSK9 inhibitors, as well as the National Health Genomics Policy Framework, will enable adoption of these recommendations. A broad implementation science strategy is, however, required to ensure that the guidance translates into benefit for all families with FH.
- Published
- 2021
- Full Text
- View/download PDF
3. The relationship between endothelial progenitor cell populations and epicardial and microvascular coronary disease-a cellular, angiographic and physiologic study.
- Author
-
Kim H Chan, Philippa J L Simpson, Andy S Yong, Louise L Dunn, Chirapan Chawantanpipat, Chijen Hsu, Young Yu, Anthony C Keech, David S Celermajer, and Martin K C Ng
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Endothelial progenitor cells (EPCs) are implicated in protection against vascular disease. However, studies using angiography alone have reported conflicting results when relating EPCs to epicardial coronary artery disease (CAD) severity. Moreover, the relationship between different EPC types and the coronary microcirculation is unknown. We therefore investigated the relationship between EPC populations and coronary epicardial and microvascular disease. METHODS: Thirty-three patients with a spectrum of isolated left anterior descending artery disease were studied. The coronary epicardial and microcirculation were physiologically interrogated by measurement of fractional flow reserve (FFR), index of microvascular resistance (IMR) and coronary flow reserve (CFR). Two distinct EPC populations (early EPC and late outgrowth endothelial cells [OECs]) were isolated from these patients and studied ex vivo. RESULTS: There was a significant inverse relationship between circulating OEC levels and epicardial CAD severity, as assessed by FFR and angiography (r=0.371, p=0.04; r=-0.358, p=0.04; respectively). More severe epicardial CAD was associated with impaired OEC migration and tubulogenesis (r=0.59, p=0.005; r=0.589, p=0.004; respectively). Patients with significant epicardial CAD (FFR
- Published
- 2014
- Full Text
- View/download PDF
4. Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys
- Author
-
Steven, Trawley, Amanda N, Stephens, Sybil A, McAuley, Jane, Speight, Christel, Hendrieckx, Sara, Vogrin, Melissa H, Lee, Barbora, Paldus, Leon A, Bach, Morton G, Burt, Neale D, Cohen, Peter G, Colman, Elizabeth A, Davis, D Jane, Holmes-Walker, Alicia J, Jenkins, Joey, Kaye, Anthony C, Keech, Kavita, Kumareswaran, Richard J, MacIsaac, Roland W, McCallum, Catriona M, Sims, Stephen N, Stranks, Vijaya, Sundararajan, Glenn M, Ward, Timothy W, Jones, and David N, O'Neal
- Subjects
Adult ,Blood Glucose ,Male ,Medical Laboratory Technology ,Diabetes Mellitus, Type 1 ,Endocrinology ,Blood Glucose Self-Monitoring ,Endocrinology, Diabetes and Metabolism ,Humans ,Hypoglycemic Agents ,Insulin ,Hypoglycemia - Abstract
There is limited evidence supporting the recommendation that drivers with insulin-treated diabetes need to start journeys with glucose90 mg/dL. Glucose levels of drivers with type 1 diabetes were monitored for 3 weeks using masked continuous glucose monitoring (CGM). Eighteen drivers (median [IQR] age 40 [35, 51] years; 11 men) undertook 475 trips (duration 15 [13, 21] min). Hypoglycemia did not occur in any trip starting with glucose90 mg/dL (92%
- Published
- 2022
5. Optimised plasma sample preparation and LC-MS analysis to support large-scale proteomic analysis of clinical trial specimens : application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial
- Author
-
Matthew B. O'Rourke, Andrzej S. Januszewski, David R. Sullivan, Imre Lengyel, Alan J. Stewart, Swati Arya, Ronald C. Ma, Sanjeev Galande, Anandwardhan A. Hardikar, Mugdha V. Joglekar, Anthony C. Keech, Alicia J. Jenkins, Mark P. Molloy, University of St Andrews. School of Medicine, University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis, University of St Andrews. Institute of Behavioural and Neural Sciences, University of St Andrews. Biomedical Sciences Research Complex, University of St Andrews. Cellular Medicine Division, and University of St Andrews. University of St Andrews
- Subjects
Proteomics ,MCC ,Biochemistry & Molecular Biology ,Mass spectrometry ,QH301 Biology ,Clinical Biochemistry ,Diabetes ,Biomarker ,Plasma ,QH301 ,ATC-NDAS ,1101 Medical Biochemistry and Metabolomics ,Fenofibrate ,SDG 3 - Good Health and Well-being ,RC Internal medicine ,RC - Abstract
Funding: This work was performed by funding from The University of Sydney (CIA Jenkins) and funds provided by the National Health and Medical Research Council (Australia) APP1147897. Purpose: Robust, affordable plasma proteomic biomarker workflows are needed for large-scale clinical studies. We evaluated aspects of sample preparation to allow LC-MS analysis of more than 1500 samples from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial of adults with type 2 diabetes. Methods: Using LC-MS with data-independent acquisition we evaluated four variables: plasma protein depletion, EDTA or citrated anti-coagulant blood collection tubes, plasma lipid depletion strategies and plasma freeze-thaw cycles. Optimised methods were applied in a pilot study of FIELD participants. Results: LC-MS of undepleted plasma conducted over a 45 min gradient yielded 172 proteins after excluding immunoglobulin isoforms. Cibachrome-blue-based depletion yielded additional proteins but with cost and time expenses, while immunodepleting albumin and IgG provided few additional identifications. Only minor variations were associated with blood collection tube type, delipidation methods and freeze-thaw cycles. From 65 batches involving over 1500 injections, the median intra-batch quantitative differences in the top 100 proteins of the plasma external standard was less than 2%. Fenofibrate altered seven plasma proteins. Conclusions and Clinical Relevance: A robust plasma handling and LC-MS proteomics workflow for abundant plasma proteins has been developed for large-scale biomarker studies that balances proteomic depth with time and resource costs. Publisher PDF
- Published
- 2023
6. Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- Author
-
Angela Sheu, Rachel L. O’Connell, Alicia J. Jenkins, Thach Tran, Paul L. Drury, David R. Sullivan, LiPing Li, Peter Colman, Richard O’Brien, Y. Antero Kesäniemi, Jacqueline R. Center, Christopher P. White, and Anthony C. Keech
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Internal Medicine - Published
- 2023
7. Review and comparison of retinal vessel calibre and geometry software and their application to diabetes, cardiovascular disease, and dementia
- Author
-
Laima Brazionis, Nicola Quinn, Sami Dabbah, Chris D. Ryan, Dennis M. Møller, Hilary Richardson, Anthony C. Keech, Andrzej S. Januszewski, Jakob Grauslund, Malin Lundberg Rasmussen, Tunde Peto, and Alicia J. Jenkins
- Subjects
Cellular and Molecular Neuroscience ,Ophthalmology ,Sensory Systems - Published
- 2023
8. Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis
- Author
-
Feifei Cheng, Andrea O. Luk, Mai Shi, Chuiguo Huang, Guozhi Jiang, Aimin Yang, Hongjiang Wu, Cadmon K.P. Lim, Claudia H.T. Tam, Baoqi Fan, Eric S.H. Lau, Alex C.W. Ng, Kwun Kiu Wong, Luke Carroll, Heung Man Lee, Alice P. Kong, Anthony C. Keech, Elaine Chow, Mugdha V. Joglekar, Stephen K.W. Tsui, Wing Yee So, Hon Cheong So, Anandwardhan A. Hardikar, Alicia J. Jenkins, Juliana C.N. Chan, and Ronald C.W. Ma
- Subjects
Cohort Studies ,Advanced and Specialized Nursing ,Diabetes Mellitus, Type 2 ,Endocrinology, Diabetes and Metabolism ,Leukocytes ,Internal Medicine ,Humans ,Prospective Studies ,Mendelian Randomization Analysis ,Middle Aged ,Telomere ,Telomere Shortening - Abstract
OBJECTIVE Several studies support associations between relative leukocyte telomere length (rLTL), a biomarker of biological aging and type 2 diabetes. This study investigates the relationship between rLTL and the risk of glycemic progression in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS In this cohort study, consecutive Chinese patients with type 2 diabetes (N = 5,506) from the Hong Kong Diabetes Register with stored baseline DNA and available follow-up data were studied. rLTL was measured using quantitative PCR. Glycemic progression was defined as the new need for exogenous insulin. RESULTS The mean (SD) age of the 5,349 subjects was 57.0 (13.3) years, and mean (SD) follow-up was 8.8 (5.4) years. Baseline rLTL was significantly shorter in the 1,803 subjects who progressed to insulin requirement compared with the remaining subjects (4.43 ± 1.16 vs. 4.69 ± 1.20). Shorter rLTL was associated with a higher risk of glycemic progression (hazard ratio [95% CI] for each unit decrease [to ∼0.2 kilobases]: 1.10 [1.06–1.14]), which remained significant after adjusting for confounders. Baseline rLTL was independently associated with glycemic exposure during follow-up (β = −0.05 [−0.06 to −0.04]). Each 1-kilobase decrease in absolute LTL was on average associated with a 1.69-fold higher risk of diabetes progression (95% CI 1.35–2.11). Two-sample Mendelian randomization analysis showed per 1-unit genetically decreased rLTL was associated with a 1.38-fold higher risk of diabetes progression (95% CI 1.12–1.70). CONCLUSIONS Shorter rLTL was significantly associated with an increased risk of glycemic progression in individuals with type 2 diabetes, independent of established risk factors. Telomere length may be a useful biomarker for glycemic progression in people with type 2 diabetes.
- Published
- 2022
9. Transcatheter Aortic Valve Implantation (TAVI) Versus Surgical Aortic Valve Replacement for Aortic Stenosis (SAVR): A Cost-Comparison Study
- Author
-
K. Shah, Anthony C Keech, Martin K. Ng, Daniel Elder, L. Turner, M. Doyle, Kei Woldendorp, Michael Seco, Chi Kin Law, Mai T.H. Nguyen, Michael K. Wilson, and Rachael L. Morton
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Transcatheter aortic ,medicine.medical_treatment ,law.invention ,Transcatheter Aortic Valve Replacement ,Aortic valve replacement ,Valve replacement ,Risk Factors ,law ,medicine ,Hospital discharge ,Humans ,Aged ,Retrospective Studies ,Heart Valve Prosthesis Implantation ,Cost comparison ,business.industry ,Australia ,Aortic Valve Stenosis ,medicine.disease ,Intensive care unit ,Surgery ,Stenosis ,Treatment Outcome ,Aortic Valve ,Female ,Principal diagnosis ,Cardiology and Cardiovascular Medicine ,business - Abstract
Comparative costing studies using real-world data stratified by patient case-mix, are valuable to decision makers for making reimbursement decisions of new interventions. This study evaluated real-world hospital admissions and short-term costs of transcatheter aortic valve implantation (TAVI) and isolated surgical aortic valve replacement (SAVR) for patients with aortic stenosis, stratified by the Society of Thoracic Surgeons (STS) risk scores.Retrospective analysis of consecutive patients with a principal diagnosis of aortic stenosis who underwent isolated valve replacement at a single tertiary hospital, January 2012-December 2017. Patients were followed-up for 30 days post-procedure or until hospital discharge if index hospitalisation was greater than 30 days. Intensive care unit (ICU) and hospital length of stay (days), and costs in 2018 Australian dollars for the index procedure and 30-day follow-up were assessed. Multivariable generalised linear and two-part models with gamma distribution and log link function adjusting for Society of Thoracic Surgeons (STS) risk group and key sociodemographic characteristics were used.Of 488 patients, 61% males, median age 78 years (IQR 14 years), 221 (45%) received transcatheter aortic valve replacement (TAVI) and 267 (55%) received surgical aortic valve replacement (SAVR). STS risk scores were low (28%), intermediate (46%) and high (26%) for TAVI patients, and low (85%), intermediate (12%) and high (3%) for SAVR patients. When adjusted, TAVI length of stay was 57% shorter than SAVR (95% CI 31-83%, p0.001) for intensive care unit (ICU) admission, and 64% shorter (95% CI 47-81%, p0.001) for hospital admissions. TAVI costs were 13% lower than SAVR (95% CI 4-22%, p=0.005).This data suggests short-term health care costs are lower for patients with aortic stenosis undergoing TAVI than SAVR. A further roll-out of the TAVI program in hospitals across Australia may result in savings to the health system.
- Published
- 2021
10. Relative leucocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register
- Author
-
Baoqi Fan, Guozhi Jiang, Ronald C.W. Ma, Anthony C Keech, Feifei Cheng, Alex C.W. Ng, Claudia H. T. Tam, Luke Carroll, Andrea O.Y. Luk, Alicia J. Jenkins, Cadmon K.P. Lim, Heung Man Lee, Elaine Chow, Anandwardhan A. Hardikar, Aimin Yang, Eric S.H. Lau, Hongjiang Wu, Alice P.S. Kong, Juliana C.N. Chan, Wing-Yee So, and Mugdha V. Joglekar
- Subjects
Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Renal function ,Type 2 diabetes ,Kidney ,Real-Time Polymerase Chain Reaction ,Article ,Kidney function ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,Leukocytes ,Humans ,Prospective Studies ,Registries ,Prospective cohort study ,Telomere Shortening ,Aged ,Chinese ,Telomere length ,business.industry ,Incidence ,End-stage kidney disease ,Middle Aged ,Telomere ,medicine.disease ,Diabetes Mellitus, Type 2 ,Cohort ,Biomarker (medicine) ,Hong Kong ,Kidney Failure, Chronic ,Female ,business ,Kidney disease ,Glomerular Filtration Rate - Abstract
Aims/hypothesis Few large-scale prospective studies have investigated associations between relative leucocyte telomere length (rLTL) and kidney dysfunction in individuals with type 2 diabetes. We examined relationships between rLTL and incident end-stage kidney disease (ESKD) and the slope of eGFR decline in Chinese individuals with type 2 diabetes. Methods We studied 4085 Chinese individuals with type 2 diabetes observed between 1995 and 2007 in the Hong Kong Diabetes Register with stored baseline DNA and available follow-up data. rLTL was measured using quantitative PCR. ESKD was diagnosed based on the ICD-9 code and eGFR. Results In this cohort (mean ± SD age 54.3 ± 12.6 years) followed up for 14.1 ± 5.3 years, 564 individuals developed incident ESKD and had shorter rLTL at baseline (4.2 ± 1.2 vs 4.7 ± 1.2, p n = 3521). On Cox regression analysis, each ∆∆Ct decrease in rLTL was associated with an increased risk of incident ESKD (HR 1.21 [95% CI 1.13, 1.30], p 1c, lipids, renal function and other risk factors (HR 1.11 [95% CI 1.03, 1.19], p = 0.007). Shorter rLTL at baseline was associated with rapid decline in eGFR (>4% per year) during follow-up (unadjusted OR 1.22 [95% CI 1.15, 1.30], p p = 0.024). Conclusions/interpretation rLTL is independently associated with incident ESKD and rapid eGFR loss in individuals with type 2 diabetes. Telomere length may be a useful biomarker for the progression of kidney function and ESKD in type 2 diabetes. Graphical abstract
- Published
- 2021
11. Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―
- Author
-
Chung-Wah Siu, Peter S. Sever, Robert P. Giugliano, John Amerena, Donghoon Choi, Armando Lira Pineda, Prakash Deedwania, Min-Ji Charng, Terje R. Pedersen, Anthony C Keech, Leslie Tay, Marc S. Sabatine, Vijay K. Chopra, Chen Lu, Kazuma Oyama, Atsushi Hirayama, Wan Azman Wan Ahmad, Sabina A. Murphy, and Minao Tang
- Subjects
medicine.medical_specialty ,Statin ,medicine.drug_class ,Subgroup analysis ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,Placebo ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,Internal medicine ,Clinical endpoint ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,Unstable angina ,business.industry ,PCSK9 ,PCSK9 Inhibitors ,Cholesterol, LDL ,General Medicine ,Atherosclerosis ,medicine.disease ,Evolocumab ,Treatment Outcome ,Heart Disease Risk Factors ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Proprotein Convertase 9 ,Cardiology and Cardiovascular Medicine ,business - Abstract
BACKGROUND There are concerns that Asian patients respond differently to some medications. This study evaluated the efficacy and safety of evolocumab among Asian vs. other subjects in the FOURIER trial, which randomized stable atherosclerosis patients to receive either evolocumab or placebo.Methods and Results:Effects of adding evolocumab vs. placebo to background statin therapy on low-density lipoprotein cholesterol (LDL-C) reductions, cardiovascular outcomes, and adverse events were compared among 27,564 participants with atherosclerotic disease, according to self-reported Asian (n=2,723) vs. other (n=24,841) races followed for a median of 2.2 years in the FOURIER trial. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. At randomization, Asians had slightly lower LDL-C (median 89 [IQR 78-104] mg/dL vs. 92 [80-109] mg/dL; P
- Published
- 2021
12. Screening for diabetic retinopathy and reduced vision among Indigenous Australians in Top End primary care health services: a <scp>TEAMSnet</scp> sub‐study
- Author
-
Feibi Yang, Sven-Erik Bursell, Chris Ryan, Alicia J. Jenkins, Anthony C Keech, Sharon Atkinson-Briggs, Laima Brazionis, TEAMSnet Study Groups, and Nicola Quinn
- Subjects
Pediatrics ,medicine.medical_specialty ,genetic structures ,Population ,Vision, Low ,Indigenous ,Health services ,Cataracts ,Diabetes mellitus ,Diabetes Mellitus ,Prevalence ,Internal Medicine ,medicine ,Humans ,Mass Screening ,education ,education.field_of_study ,Diabetic Retinopathy ,Primary Health Care ,business.industry ,Australia ,Diabetic retinopathy ,medicine.disease ,eye diseases ,Impaired Vision ,Cross-Sectional Studies ,Clinical research ,business - Abstract
BACKGROUND: Diabetic retinopathy (DR) prevalence is higher in Indigenous Australians than in other Australians and is a major cause of vision loss. Consequently, timely screening and treatment is paramount, and annual eye screening is recommended for Indigenous Australians. AIMS: To assess the prevalence of DR, reduced vision, and DR treatment coverage among Indigenous Australian adults with diabetes attending Top End Indigenous primary care health services. METHODS: A cross-sectional DR screening study conducted from November 2013-December 2015 in two very remote Northern Territory Aboriginal primary healthcare services. RESULTS: In 287 subjects, the prevalence of non-proliferative DR, proliferative DR, and clinically significant diabetic macular oedema (CSMO) was 37.3%, 5.4% and 9.0%, respectively. Treatment coverage for PDR was 60% (of ten patients) and for CSMO was 17% (of 23 patients). Vision data were available from 122 participants at one site. The proportion with normal vision, reduced vision, impaired vision and blindness was 31.1%, 52.5%, 15.6% and 0.8%, respectively. Overall, ungradable monocular image sets (46%) were associated with poorer quality images and missing protocol images (both p
- Published
- 2021
13. <scp>Guideline‐based</scp> audit of the hospital management of heart failure with reduced ejection fraction
- Author
-
Douglas Drak, Jordan Fulcher, Jens Kilian, James J. H. Chong, Rominder Grover, Andrew P. Sindone, Mark Adams, Jo‐Dee Lattimore, and Anthony C. Keech
- Subjects
Internal Medicine - Abstract
Heart failure is a major burden in Australia in terms of morbidity, mortality and healthcare expenditure. Multiple evidence-based therapies are recommended for heart failure with reduced ejection fraction (HFrEF), but data on physician adherence to therapy guidelines are limited.To compare use of HFrEF therapies against current evidence-based guidelines in an Australian hospital inpatient population.A retrospective review of patients admitted with a principal diagnosis of HFrEF across six metropolitan hospitals in Sydney, Australia, between January 2015 and June 2016. Use of medical and device therapies was compared with guideline recommendations using individual patient indications/contraindications. Readmission and mortality data were collected for a 1-year period following the admission.Of the 1028 HFrEF patients identified, 39 were being managed with palliative intent, leaving 989 patients for the primary analysis. Use of beta-blockers (87.7% actual use/93.6% recommended use) and diuretics (88.4%/99.3%) was high among eligible patients. There were large evidence-practice gaps for angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB; 66.4%/89.0%) and aldosterone antagonists (41.0%/77.1%). In absolute terms, use of these therapies each increased by over 11% from admission. Ivabradine (11.5%/21.2%), automated internal cardiac defibrillators (29.5%/66.1%) and cardiac resynchronisation therapy (13.1%/28.7%) were used in a minority of eligible patients. Over the 1-year follow-up period, the mortality rate was 14.8%, and 44.2% of patients were readmitted to hospital at least once.Hospitalisation is a key mechanism for initiation of HFrEF therapies. The large evidence-practice gaps for ACEI/ARB and aldosterone antagonists represent potential avenues for improved HFrEF management.
- Published
- 2022
14. Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial
- Author
-
Anthony C Keech, Sabina A. Murphy, Minao Tang, Kazuma Oyama, Brian A. Bergmark, Jeffrey L. Saver, Marc S. Sabatine, Robert P. Giugliano, Andrea Ruzza, Peter S. Sever, and Marc P. Bonaca
- Subjects
medicine.medical_specialty ,Acute limb ischaemia ,business.industry ,PCSK9 ,medicine.medical_treatment ,Hazard ratio ,Cerebral Revascularization ,Antibodies, Monoclonal, Humanized ,Revascularization ,medicine.disease ,Rate ratio ,Brain Ischemia ,Stroke ,Evolocumab ,Internal medicine ,Cardiology ,Humans ,Medicine ,Myocardial infarction ,Proprotein Convertase 9 ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims We assessed the impact of the proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab on acute arterial events across all vascular territories, including coronary, cerebrovascular, and peripheral vascular beds, in patients with established atherosclerotic cardiovascular disease (ASCVD). Methods and results In the FOURIER trial, 27 564 patients with stable ASCVD on statin therapy were randomly assigned to evolocumab or placebo. Acute arterial events were a composite of acute coronary (coronary heart disease death, myocardial infarction, or urgent coronary revascularization), cerebrovascular (ischaemic stroke, transient ischaemic attack, or urgent cerebral revascularization), or peripheral vascular (acute limb ischaemia, major amputation, or urgent peripheral revascularization) events. Of the 2210 first acute arterial events, 74% were coronary, 22% were cerebrovascular, and 4% were peripheral vascular. Evolocumab reduced first acute arterial events by 19% (hazard ratio [HR] 0.81 [95% confidence interval 0.74–0.88]; P Conclusion The addition of the PCSK9 inhibitor evolocumab to statin therapy reduced acute arterial events across all vascular territories with a robust effect over time, indicating a pan-vascular impact of aggressive lipid-lowering therapy on these acute and clinically meaningful events. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT01764633.
- Published
- 2021
15. Hybrid closed‐loop therapy with a first‐generation system increases confidence and independence in diabetes management in youth with type 1 diabetes
- Author
-
Alison, Roberts, Leanne, Fried, Julie, Dart, Martin, de Bock, Janice, Fairchild, Bruce, King, Geoffrey R, Ambler, Fergus, Cameron, Sybil A, McAuley, Anthony C, Keech, Alicia, Jenkins, David N, O Neal, Elizabeth A, Davis, Timothy W, Jones, and Mary B, Abraham
- Subjects
Adult ,Blood Glucose ,Young Adult ,Diabetes Mellitus, Type 1 ,Insulin Infusion Systems ,Endocrinology ,Adolescent ,Blood Glucose Self-Monitoring ,Endocrinology, Diabetes and Metabolism ,Internal Medicine ,Humans ,Hypoglycemic Agents ,Insulin - Abstract
Hybrid closed-loop (HCL) therapy improves glycaemic control in adolescents with type 1 diabetes; however, little is known about their lived experience using these systems. The aim of this study was to explore the lived experiences of youth with type 1 diabetes using HCL therapy, and their parents, to provide insight into their lived experiences.Adolescents and young adults aged 12-25 years, who used Medtronic MiniMed™ 670G HCL system during a 6-month randomised clinical trial, and their parents, were invited to participate in a semi-structured interview at the end of the study. Open-ended questions were used to explore the lived experiences of families using HCL. The interviews were audio-recorded, transcribed and analysed using thematic analysis to determine the main themes.In all, 17 young people with type 1 diabetes mean ± SD age: 17.5 ± 4.2 years, diabetes duration: 11.0 ± 4.9 years and HbABoth youth and parents acknowledged the benefits of this first-generation HCL system in improving glycaemic outcomes and in providing flexibility and independence. These lived experiences provide valuable information in the introduction and provision of targeted education with HCL therapy.
- Published
- 2022
16. Insulin micro-secretion in Type 1 diabetes and related microRNA profiles
- Author
-
Anthony C Keech, Yoon Hi Cho, Ryan J. Farr, Emma S. Scott, David N O'Neal, Anandwardhan A. Hardikar, Paul Z. Benitez-Aguirre, Mugdha V. Joglekar, Andrzej S. Januszewski, Luke M. Carroll, Alicia J. Jenkins, Maria E. Craig, Yik Wen Loh, Wilson K. M. Wong, and Kim C. Donaghue
- Subjects
Blood Glucose ,Male ,0301 basic medicine ,Diabetes duration ,medicine.medical_treatment ,Autoimmunity ,0302 clinical medicine ,Insulin-Secreting Cells ,Insulin Secretion ,Medicine ,Child ,Aged, 80 and over ,Multidisciplinary ,C-Peptide ,Age Factors ,Middle Aged ,Type 1 diabetes ,Female ,Adult ,medicine.medical_specialty ,Adolescent ,Science ,030209 endocrinology & metabolism ,Article ,Young Adult ,03 medical and health sciences ,Diabetes mellitus ,Internal medicine ,microRNA ,Humans ,Secretion ,Circulating MicroRNA ,Insulin secretion ,Aged ,Autoantibodies ,Glycated Hemoglobin ,business.industry ,Insulin ,medicine.disease ,MicroRNAs ,Diabetes Mellitus, Type 1 ,030104 developmental biology ,Endocrinology ,Gene Expression Regulation ,Genetic markers ,Age of onset ,business ,Biomarkers - Abstract
The aim of this cross-sectional study was to compare plasma C-peptide presence and levels in people without diabetes (CON) and with Type 1 diabetes and relate C-peptide status to clinical factors. In a subset we evaluated 50 microRNAs (miRs) previously implicated in beta-cell death and associations with clinical status and C-peptide levels. Diabetes age of onset was stratified as adult (≥ 18 y.o) or childhood ( 20 years. Plasma C-peptide was measured by ultrasensitive ELISA. Plasma miRs were quantified using TaqMan probe-primer mix on an OpenArray platform. C-peptide was detectable in 55.3% of (n = 349) people with diabetes, including 64.1% of adults and 34.0% of youth with diabetes, p p p = 0.02, respectively]. In the childhood-onset group more people with longer diabetes duration (> 20 years) had detectable C-peptide (60%) than in those with shorter diabetes duration (39%, p for trend
- Published
- 2021
17. Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections
- Author
-
Christel Hendrieckx, Kavita Kumareswaran, Sara Vogrin, D Jane Holmes-Walker, Jane Speight, Leon A. Bach, Elizabeth A. Davis, David N O'Neal, Martin de Bock, Mary B Abraham, Timothy W. Jones, Roland W. McCallum, Richard J MacIsaac, Steven Trawley, Vijaya Sundararajan, Morton G. Burt, Catriona M. Sims, Alicia J. Jenkins, Anthony C Keech, Joey Kaye, Peter G. Colman, Barbora Paldus, Stephen N Stranks, Neale Cohen, Glenn M. Ward, Sybil A McAuley, and Melissa H Lee
- Subjects
Adult ,Blood Glucose ,Insulin pump ,medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Hypoglycemia ,03 medical and health sciences ,Insulin Infusion Systems ,0302 clinical medicine ,Endocrinology ,Interquartile range ,Internal medicine ,Blood Glucose Self-Monitoring ,Diabetes mellitus ,medicine ,Humans ,Hypoglycemic Agents ,Insulin ,030212 general & internal medicine ,Glycated Hemoglobin ,Type 1 diabetes ,business.industry ,Australia ,nutritional and metabolic diseases ,medicine.disease ,Confidence interval ,Medical Laboratory Technology ,Diabetes Mellitus, Type 1 ,business - Abstract
Background: This prerandomization analysis from the Australian HCL-Adult trial (registration number: ACTRN12617000520336) compared masked continuous glucose monitoring (CGM) metrics among adults using insulin pumps versus multiple daily injections (MDIs), who were all self-monitoring blood glucose (SMBG). Methods: Adults with type 1 diabetes, using an insulin pump or MDIs without real-time CGM (and entering a trial of closed-loop technology), were eligible. MDI users were given an insulin dosage calculator. All participants received diabetes and carbohydrate-counting education, then wore masked CGM sensors for 3 weeks. Ethics Approval: HREC-D 088/16 Results: Adults using MDIs (n = 61) versus pump (n = 59) did not differ by age, sex, diabetes duration, insulin total daily dose, or HbA1c at baseline. After education, median (interquartile range) CGM time in range (TIR) 70-180 mg/dL (3.9-10.0 mmol/L) was 54% (47, 62) for those using MDIs and 56% (48, 66) for those using pump (P = 0.40). All CGM metrics were equivalent for 24 h/day for MDI and pump users. Overnight, those using MDIs (vs. pump) spent more time with glucose
- Published
- 2021
18. Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL
- Author
-
Anthony C Keech, Peter S. Sever, Andrea Ruzza, Robert P. Giugliano, Jeong-Gun Park, Nicholas A Marston, and Marc S. Sabatine
- Subjects
medicine.medical_specialty ,Cholesterol ,business.industry ,Low density lipoprotein cholesterol ,Cholesterol, LDL ,medicine.disease ,Cardiovascular System ,Article ,Cardiovascular Physiological Phenomena ,Coronary artery disease ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Cardiovascular Diseases ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,Public Health Surveillance ,Health Impact Assessment ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers - Published
- 2021
19. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials
- Author
-
A. Mosterd, Anthony C Keech, David C Tong, Charley A. Budgeon, Jan H. Cornel, Jaimie Layland, Jan G.P. Tijssen, Peter J. Kelly, Aernoud T L Fiolet, Peter L. Thompson, Stefan M. Nidorf, Sanjit S. Jolly, John Eikelboom, Tjerk S.J. Opstal, Cardiology, and ACS - Heart failure & arrhythmias
- Subjects
medicine.medical_specialty ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Myocardial Infarction ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Stroke ,Randomized Controlled Trials as Topic ,Coronary disease ,business.industry ,Incidence (epidemiology) ,Atherosclerosis ,medicine.disease ,Confidence interval ,Treatment Outcome ,Major adverse cardiovascular events ,Relative risk ,Colchicine ,Cardiology and Cardiovascular Medicine ,business ,Mace - Abstract
Aims Recent randomized trials demonstrated a benefit of low-dose colchicine added to guideline-based treatment in patients with recent myocardial infarction or chronic coronary disease. We performed a systematic review and meta-analysis to obtain best estimates of the effects of colchicine on major adverse cardiovascular events (MACE). Methods and results We searched the literature for randomized clinical trials of long-term colchicine in patients with atherosclerosis published up to 1 September 2020. The primary efficacy endpoint was MACE, the composite of myocardial infarction, stroke, or cardiovascular death. We combined the results of five trials that included 11 816 patients. The primary endpoint occurred in 578 patients. Colchicine reduced the risk for the primary endpoint by 25% [relative risk (RR) 0.75, 95% confidence interval (CI) 0.61–0.92; P = 0.005], myocardial infarction by 22% (RR 0.78, 95% CI 0.64–0.94; P = 0.010), stroke by 46% (RR 0.54, 95% CI 0.34–0.86; P = 0.009), and coronary revascularization by 23% (RR 0.77, 95% CI 0.66–0.90; P Conclusion Our meta-analysis indicates that low-dose colchicine reduced the risk of MACE as well as that of myocardial infarction, stroke, and the need for coronary revascularization in a broad spectrum of patients with coronary disease. There was no difference in all-cause mortality and fewer cardiovascular deaths were counterbalanced by more non-cardiovascular deaths.
- Published
- 2021
20. Transesophageal Echocardiographic Diagnosis of Cardiac Rupture During Extracorporeal Membrane Oxygenation–Assisted Percutaneous Coronary Intervention
- Author
-
James C. Weaver, Bruce Cartwright, Boris Waldman, Anthony C Keech, David D'Silva, and Michael Byrom
- Subjects
medicine.medical_specialty ,Percutaneous ,business.industry ,medicine.medical_treatment ,Cardiac Rupture ,Percutaneous coronary intervention ,030204 cardiovascular system & hematology ,Revascularization ,medicine.disease ,Pericardial effusion ,Intracardiac injection ,03 medical and health sciences ,surgical procedures, operative ,0302 clinical medicine ,Anesthesiology and Pain Medicine ,030202 anesthesiology ,Internal medicine ,medicine ,Extracorporeal membrane oxygenation ,Cardiology ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business - Abstract
Left ventricular free wall rupture is a feared complication of myocardial infarction and revascularization therapies. Transesophageal echocardiography (TEE) has an established role in cardiac surgery and a growing role in percutaneous intracardiac procedures, complex PCI and Extra-Corporeal Membrane Oxygenation (ECMO). This report concerns a 91-year old patient who underwent complex Extra-Corporeal Membrane Oxygenation (ECMO) assisted PCI. Despite successful angiography, the procedure was complicated by left ventricular free wall rupture. Transesophageal echocardiography (TEE) allowed for rapid diagnosis of the complication and associated pericardial effusion and facilitated surgical management of the effusion as well as the ultimate decision to palliate. The report highlights the ever-present risk of cardiac rupture post revascularization as well as the value of TEE in the rapid diagnosis of this complication and as a guide to anesthetic and procedural management in complex percutaneous cases
- Published
- 2021
21. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease
- Author
-
Benjamin M. Scirica, Christian T. Ruff, Robert P. Giugliano, Christopher P. Cannon, Peter S. Sever, Eugene Braunwald, Robert F. Storey, Frederick K. Kamanu, Marc S. Sabatine, Yared Gurmu, Steven A. Lubitz, Christopher D. Anderson, Elliott M. Antman, Parth N Patel, Marc P. Bonaca, Philippe Gabriel Steg, Patrick T. Ellinor, Michelle L. O'Donoghue, Lu-Chen Weng, Anthony C Keech, Itamar Raz, Ofri Mosenzon, Marc Cohen, Deepak L. Bhatt, Francesco Nordio, Nicholas A Marston, Carolina Roselli, and Giorgio M. Melloni
- Subjects
Male ,medicine.medical_specialty ,Genotyping Techniques ,MEDLINE ,030204 cardiovascular system & hematology ,Risk Assessment ,Article ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,In patient ,Genetic risk ,Stroke ,Aged ,Ischemic Stroke ,Genetic association ,Aged, 80 and over ,Metabolic Syndrome ,business.industry ,Atrial fibrillation ,medicine.disease ,Cardiometabolic disease ,Ischemic stroke ,Female ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery ,Genome-Wide Association Study - Abstract
Background: Genome-wide association studies have identified single-nucleotide polymorphisms that are associated with an increased risk of stroke. We sought to determine whether a genetic risk score (GRS) could identify subjects at higher risk for ischemic stroke after accounting for traditional clinical risk factors in 5 trials across the spectrum of cardiometabolic disease. Methods: Subjects who had consented for genetic testing and who were of European ancestry from the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation), SOLID-TIMI 52 (Stabilization of Plaques Using Darapladib), SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus), PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin), and FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) trials were included in this analysis. A set of 32 single-nucleotide polymorphisms associated with ischemic stroke was used to calculate a GRS in each patient and identify tertiles of genetic risk. A Cox model was used to calculate hazard ratios for ischemic stroke across genetic risk groups, adjusted for clinical risk factors. Results: In 51 288 subjects across the 5 trials, a total of 960 subjects had an ischemic stroke over a median follow-up period of 2.5 years. After adjusting for clinical risk factors, a higher GRS was strongly and independently associated with increased risk for ischemic stroke ( P trend=0.009). In comparison with individuals in the lowest third of the GRS, individuals in the middle and top tertiles of the GRS had adjusted hazard ratios of 1.15 (95% CI, 0.98–1.36) and 1.24 (95% CI 1.05–1.45) for ischemic stroke, respectively. Stratification into subgroups revealed that the performance of the GRS appeared stronger in the primary prevention cohort with an adjusted hazard ratio for the top versus lowest tertile of 1.27 (95% CI, 1.04–1.53), in comparison with an adjusted hazard ratio of 1.06 (95% CI, 0.81–1.41) in subjects with previous stroke. In an exploratory analysis of patients with atrial fibrillation and CHA 2 DS 2 -VASc score of 2, high genetic risk conferred a 4-fold higher risk of stroke and an absolute risk equivalent to those with CHA 2 DS 2 -VASc score of 3. Conclusions: Across a broad spectrum of subjects with cardiometabolic disease, a 32–single-nucleotide polymorphism GRS was a strong, independent predictor of ischemic stroke. In patients with atrial fibrillation but lower CHA 2 DS 2 -VASc scores, the GRS identified patients with risk comparable to those with higher CHA 2 DS 2 -VASc scores.
- Published
- 2021
22. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease
- Author
-
Ofri Mosenzon, Marc P. Bonaca, Ilaria Cavallari, Anthony C Keech, Itamar Raz, Marc Cohen, Philippe Gabriel Steg, Nicholas A Marston, Yared Gurmu, Marc S. Sabatine, Robert F. Storey, Carolina Roselli, Giorgio E. M. Melloni, Benjamin M. Scirica, Deepak L. Bhatt, Patrick T. Ellinor, Christina J.-Y. Lee, Frederick K. Kamanu, Christian T. Ruff, Robert P. Giugliano, Eugene Braunwald, and Steven A. Lubitz
- Subjects
Male ,medicine.medical_specialty ,pulmonary embolism ,venous thromboembolism ,Article ,Risk Factors ,Internal medicine ,genomics ,Humans ,Medicine ,In patient ,genetics ,Myocardial infarction ,cardiovascular diseases ,Genetic risk ,Aged ,Proportional Hazards Models ,Metabolic Syndrome ,business.industry ,General Medicine ,Middle Aged ,Cardiometabolic disease ,medicine.disease ,Pulmonary embolism ,myocardial infarction ,Female ,Proprotein Convertase 9 ,business ,Venous thromboembolism - Abstract
Background: Venous thromboembolism (VTE) is a major cause of cardiovascular morbidity and mortality and has a known genetic contribution. We tested the performance of a genetic risk score for its ability to predict VTE in 3 cohorts of patients with cardiometabolic disease. Methods: We included patients from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk), PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin), and SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) trials (history of a major atherosclerotic cardiovascular event, myocardial infarction, and diabetes, respectively) who consented for genetic testing and were not on baseline anticoagulation. We calculated a VTE genetic risk score based on 297 single nucleotide polymorphisms with established genome-wide significance. Patients were divided into tertiles of genetic risk. Cox proportional hazards models were used to calculate hazard ratios for VTE across genetic risk groups. The polygenic risk score was compared with available clinical risk factors (age, obesity, smoking, history of heart failure, and diabetes) and common monogenic mutations. Results: A total of 29 663 patients were included in the analysis with a median follow-up of 2.4 years, of whom 174 had a VTE event. There was a significantly increased gradient of risk across VTE genetic risk tertiles ( P -trend P =0.004) and 2.70-fold (95% CI, 1.81–4.06; P P Conclusions: In a broad spectrum of patients with cardiometabolic disease, a polygenic risk score is a strong, independent predictor of VTE after accounting for available clinical risk factors, identifying 1/3 of patients who have a risk of VTE comparable to that seen with established monogenic thrombophilia.
- Published
- 2021
23. A model of culturally‐informed integrated diabetes education and eye screening in indigenous primary care services and specialist diabetes clinics: Study protocol
- Author
-
Chris Ryan, Sharon Atkinson-Briggs, Anthony C Keech, Laima Brazionis, and Alicia J. Jenkins
- Subjects
Adult ,medicine.medical_specialty ,Victoria ,Referral ,Health literacy ,03 medical and health sciences ,0302 clinical medicine ,Diabetes management ,Diabetes mellitus ,Diabetes Mellitus ,medicine ,Humans ,Mass Screening ,030212 general & internal medicine ,Health Education ,General Nursing ,Mass screening ,Diabetic Retinopathy ,Primary Health Care ,030504 nursing ,business.industry ,Diabetic retinopathy ,medicine.disease ,Family medicine ,Health education ,0305 other medical science ,business ,Retinopathy - Abstract
To improve diabetes management in Indigenous Australians using an integrated nurse-led model of diabetes education and eye screening in indigenous primary care and specialist diabetes clinics.A pre-post study.This study will be implemented in indigenous primary care and specialist diabetes clinics in Victoria, Australia. Participants recruited to the study will be existing adult patient with diagnosed diabetes attending study sites. A nurse-credentialled diabetes educator and certified retinal imager will deliver three study components: (a) retinal photography as a diabetic retinopathy screening and patient engagement tool; (b) lifestyle and behaviour surveys, administered at baseline and at the final visit, in 12 months. Findings from the surveys and participants' retinal images will be used to guide; and (c) personalized diabetes education. The primary outcomes are participant adherence to diabetic eye screening recommendations and health service diabetic retinopathy screening coverage. Secondary outcomes are baseline DR prevalence and changes in clinical and lifestyle risk factor levels, diabetes knowledge and satisfaction with diabetes care.Compared with non-indigenous Australians, Indigenous Australians have a high prevalence of diabetic retinopathy and blindness, low adherence to eye screening recommendations and suboptimal health literacy. Nurse-credentialled diabetes educators can be trained to incorporate retinal imaging and eye screening into their clinical practice to give image-based diabetes education to facilitate diabetic retinopathy management.Credentialled nurse diabetes educators who integrate eye screening and diabetes education can facilitate timelier diabetic retinopathy screening, referral pathways and treatment of sight-threatening retinopathy. We believe that this model of integrated diabetes education and eye screening will also improve adherence to eye screening recommendations, population screening coverage, health literacy, risk factor levels and diabetes self-care.ANZCTRN1261800120435.目的: 通过在当地初级护理服务和糖尿病专科诊所使用糖尿病教育与眼病筛查的综合护士主导模式, 促进澳大利亚原住民的糖尿病管理。 设计: 一项前后研究。 方法: 此项研究将在澳大利亚维多利亚州的当地初级护理和糖尿病专科诊所实施。此项研究将招募现有成年糖尿病患者的参与者。一名具备护理资质的糖尿病教育者和经认证的视网膜成像仪将提供三个研究组成部分: (a)作为糖尿病视网膜病变筛查和患者参与工具的视网膜成像仪; (b) 生活方式和行为调查, 在12个月的基线检查和最后就诊时进行。调查结果和参与者的视网膜图像将用于指导; (c) 个性化糖尿病教育。主要结果是参与者遵守糖尿病眼筛查建议和健康服务糖尿病视网膜病变筛查覆盖率。次要结果是基线DR患病率、临床和生活方式危险因素水平的变化、糖尿病知识和对糖尿病护理的满意度。 讨论: 与非澳大利亚原住民相比, 澳大利亚原住民患有糖尿病视网膜病变和失明几率较高, 对眼病筛查建议的依从性较低, 且健康素养较差。具备护理资质的糖尿病教育者可接受培训, 将视网膜成像和眼病筛查纳入其临床实践, 以提供基于图像的糖尿病教育, 促进糖尿病视网膜病变的管理。 影响: 有资质的糖尿病护理教育者结合了眼病筛查和糖尿病教育, 因此可促进及时的糖尿病视网膜病变筛查、转诊途径和威胁视力的视网膜病变的治疗。我们相信, 这种糖尿病教育和眼病筛查的综合模式还将提高对眼病筛查建议、人群筛查覆盖率、健康素养、风险因素水平和糖尿病自我护理的依从性。 临床试验注册: ANZCTRN1261800120435.
- Published
- 2021
24. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial
- Author
-
Bronwyn G. A. Stuckey, Anthony C Keech, Gary A. Wittert, Mathis Grossmann, Val Gebski, Bu B. Yeap, Robert I McLachlan, Warrick J. Inder, David J. Handelsman, Mark Daniel, David Jesudason, Kristy P. Robledo, Alicia J. Jenkins, Ann J. Conway, Karen Bracken, Mark Ng Tang Fui, Wendy Hague, and Carolyn A. Allan
- Subjects
medicine.medical_specialty ,Intention-to-treat analysis ,business.industry ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Type 2 diabetes ,Overweight ,medicine.disease ,Placebo ,law.invention ,Impaired glucose tolerance ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Randomized controlled trial ,law ,Diabetes mellitus ,Relative risk ,Internal medicine ,Internal Medicine ,medicine ,030212 general & internal medicine ,medicine.symptom ,business - Abstract
Summary Background Men who are overweight or obese frequently have low serum testosterone concentrations, which are associated with increased risk of type 2 diabetes. We aimed to determine whether testosterone treatment prevents progression to or reverses early type 2 diabetes, beyond the effects of a community-based lifestyle programme. Methods T4DM was a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial done at six Australian tertiary care centres. Men aged 50–74 years, with a waist circumference of 95 cm or higher, a serum testosterone concentration of 14·0 nmol/L or lower but without pathological hypogonadism, and impaired glucose tolerance (oral glucose tolerance test [OGTT] 2-h glucose 7·8–11·0 mmol/L) or newly diagnosed type 2 diabetes (provided OGTT 2-h glucose ≤15·0 mmol/L) were enrolled in a lifestyle programme and randomly assigned (1:1) to receive an intramuscular injection of testosterone undecanoate (1000 mg) or placebo at baseline, 6 weeks, and then every 3 months for 2 years. Randomisation was done centrally, including stratification by centre, age group, waist circumference, 2-h OGTT glucose, smoking, and first-degree family history of type 2 diabetes. The primary outcomes at 2 years were type 2 diabetes (2-h OGTT glucose ≥11·1 mmol/L) and mean change from baseline in 2-h OGTT glucose, assessed by intention to treat. For safety assessment, we did a masked monitoring of haematocrit and prostate-specific antigen, and analysed prespecified serious adverse events. This study is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12612000287831. Findings Between Feb 5, 2013, and Feb 27, 2017, of 19 022 men who were pre-screened, 1007 (5%) were randomly assigned to the placebo (n=503) and testosterone (n=504) groups. At 2 years, 2-h glucose of 11·1 mmol/L or higher on OGTT was reported in 87 (21%) of 413 participants with available data in the placebo group and 55 (12%) of 443 participants in the testosterone group (relative risk 0·59, 95% CI 0·43 to 0·80; p=0·0007). The mean change from baseline 2-h glucose was −0·95 mmol/L (SD 2·78) in the placebo group and −1·70 mmol/L (SD 2·47) in the testosterone group (mean difference −0·75 mmol/L, −1·10 to −0·40; p Interpretation Testosterone treatment for 2 years reduced the proportion of participants with type 2 diabetes beyond the effects of a lifestyle programme. Increases in haematocrit might be treatment limiting. Longer-term durability, safety, and cardiovascular effects of the intervention remain to be further investigated. Funding Australian National Health and Medical Research Council, Bayer, Eli Lilly, University of Adelaide, and WW (formerly Weight Watchers).
- Published
- 2021
25. REDUCTION IN TOTAL CARDIOVASCULAR EVENTS WITH THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE COMBINED FOURIER AND FOURIER OPEN-LABEL EXTENSION (OLE) STUDIES
- Author
-
Sabina Murphy, Michelle L. O'Donoghue, Stephen Wiviott, Dan Atar, Anthony C. Keech, Julia Kuder, KyungAh Im, Jose Flores-Arredondo, J. Antonio, G. Lopez, Mary Elliott, Bei Wang, Maria Laura Monsalvo, Siddique A. Abbasi, Robert P. Giugliano, and Marc Steven Sabatine
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
26. Corrigendum to 'Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy' [Diab. Res. Clin. Pract. 186 (2022) 109835]
- Author
-
Benjamin N. Rao, Nicola Quinn, Andrzej S. Januszewski, Tunde Peto, Laima Brazionis, Nanda Aryal, Rachel L. O'Connell, Liping Li, Paula Summanen, Russell Scott, Justin O'Day, Anthony C. Keech, and Alicia J. Jenkins
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Internal Medicine ,General Medicine - Published
- 2023
27. Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy
- Author
-
Petr Jarolim, Marc S. Sabatine, Nicholas A Marston, Huei Wang, Anthony C Keech, David A. Morrow, Minao Tang, Kazuma Oyama, Robert P. Giugliano, Peter S. Sever, and Armando Lira Pineda
- Subjects
medicine.medical_specialty ,biology ,Cholesterol ,business.industry ,Troponin ,chemistry.chemical_compound ,Evolocumab ,chemistry ,Physiology (medical) ,Internal medicine ,High sensitivity troponin ,biology.protein ,medicine ,Cardiology ,Cardiology and Cardiovascular Medicine ,business - Published
- 2021
28. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials
- Author
-
Anthony C Keech, Nicholas A Marston, Christopher P. Cannon, Eugene Braunwald, KyungAh Im, Marc S. Sabatine, Peter S. Sever, Baris Gencer, and Robert P. Giugliano
- Subjects
Acute coronary syndrome ,medicine.medical_specialty ,Statin ,medicine.drug_class ,Myocardial Infarction ,030204 cardiovascular system & hematology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Ezetimibe ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Myocardial infarction ,Stroke ,Aged ,Randomized Controlled Trials as Topic ,business.industry ,Cholesterol ,Anticholesteremic Agents ,PCSK9 ,Cholesterol, LDL ,General Medicine ,medicine.disease ,Treatment Outcome ,chemistry ,Cardiovascular Diseases ,Relative risk ,business ,Risk Reduction Behavior ,medicine.drug - Abstract
Summary Background The clinical benefit of LDL cholesterol lowering treatment in older patients remains debated. We aimed to summarise the evidence of LDL cholesterol lowering therapies in older patients. Methods In this systematic review and meta-analysis, we searched MEDLINE and Embase for articles published between March 1, 2015, and Aug 14, 2020, without any language restrictions. We included randomised controlled trials of cardiovascular outcomes of an LDL cholesterol-lowering drug recommended by the 2018 American College of Cardiology and American Heart Association guidelines, with a median follow-up of at least 2 years and data on older patients (aged ≥75 years). We excluded trials that exclusively enrolled participants with heart failure or on dialysis because guidelines do not recommend lipid-lowering therapy in such patients who do not have another indication. We extracted data for older patients using a standardised data form for aggregated study-level data. We meta-analysed the risk ratio (RR) for major vascular events (a composite of cardiovascular death, myocardial infarction or other acute coronary syndrome, stroke, or coronary revascularisation) per 1 mmol/L reduction in LDL cholesterol. Findings Data from six articles were included in the systematic review and meta-analysis, which included 24 trials from the Cholesterol Treatment Trialists' Collaboration meta-analysis plus five individual trials. Among 244 090 patients from 29 trials, 21 492 (8·8%) were aged at least 75 years, of whom 11 750 (54·7%) were from statin trials, 6209 (28·9%) from ezetimibe trials, and 3533 (16·4%) from PCSK9 inhibitor trials. Median follow-up ranged from 2·2 years to 6·0 years. LDL cholesterol lowering significantly reduced the risk of major vascular events (n=3519) in older patients by 26% per 1 mmol/L reduction in LDL cholesterol (RR 0·74 [95% CI 0·61–0·89]; p=0·0019), with no statistically significant difference with the risk reduction in patients younger than 75 years (0·85 [0·78–0·92]; pinteraction=0·37). Among older patients, RRs were not statistically different for statin (0·82 [0·73–0·91]) and non-statin treatment (0·67 [0·47–0·95]; pinteraction=0·64). The benefit of LDL cholesterol lowering in older patients was observed for each component of the composite, including cardiovascular death (0·85 [0·74–0·98]), myocardial infarction (0·80 [0·71–0·90]), stroke (0·73 [0·61–0·87]), and coronary revascularisation (0·80 [0·66–0·96]). Interpretation In patients aged 75 years and older, lipid lowering was as effective in reducing cardiovascular events as it was in patients younger than 75 years. These results should strengthen guideline recommendations for the use of lipid-lowering therapies, including non-statin treatment, in older patients. Funding None.
- Published
- 2020
29. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention
- Author
-
Remo H.M. Furtado, Antônio Aurélio Fagundes, Kazuma Oyama, Thomas A. Zelniker, Minao Tang, Julia F. Kuder, Sabina A. Murphy, Andrew Hamer, Huei Wang, Anthony C. Keech, Robert P. Giugliano, Marc S. Sabatine, and Brian A. Bergmark
- Subjects
Percutaneous Coronary Intervention ,Treatment Outcome ,Risk Factors ,Anticholesteremic Agents ,Myocardial Infarction ,Humans ,cardiovascular diseases ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Proprotein Convertase 9 ,Antibodies, Monoclonal, Humanized ,Cardiology and Cardiovascular Medicine - Abstract
Background: Patients with prior percutaneous coronary intervention (PCI) are at high residual risk for multiple types of coronary events within and beyond the stented lesion. This risk might be mitigated by more intensive LDL-C (low-density lipoprotein cholesterol)-lowering beyond just with statin therapy. Methods: FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) randomized 27 564 patients with stable atherosclerotic disease on statin to the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab or placebo with a median follow-up of 2.2 years. The end points of interest were major adverse cardiovascular events (MACE; a composite of cardiovascular death, myocardial infarction, stroke, unstable angina or coronary revascularization), and major coronary events (a composite of coronary heart death, myocardial infarction, or coronary revascularization). We compared the risk of MACE and the magnitude of relative and absolute risk reductions with evolocumab in patients with and without prior PCI. Results: Seventeen thousand seventy-three patients had prior PCI. In the placebo arm, those with prior PCI had higher rates of MACE (13.2% versus 8.3%; hazard ratio [HR] adj 1.61 [95% CI, 1.42–1.84]; P adj , 1.72 [95% CI, 1.49–1.99]; P P interaction 0.51; major coronary events: HR, 0.82 [0.75–0.90] versus HR, 0.88 [0.75–1.04]; P interaction 0.42). Absolute risk reductions for MACE were 2.0% versus 0.9% ( P interaction 0.14) and for major coronary events 2.0% versus 0.7% ( P interaction 0.045). In those with prior PCI, the effect of evolocumab on coronary revascularization (HR, 0.76 [0.69–0.85]) was directionally consistent across types of revascularization procedures: coronary artery bypass grafting (HR, 0.71 [0.54–0.94]); any PCI (HR, 0.77 [0.69–0.86]); PCI for de novo lesions (HR, 0.76 [0.66–0.88]); and PCI for stent failure or graft lesions (HR, 0.76 [0.63–0.91]). Conclusions: Evolocumab reduces the risk of MACE in patients with prior PCI including the risk of coronary revascularization, with directionally consistent effects across several types of revascularization procedures, including coronary artery bypass grafting and PCI for stent or graft failure. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01764633.
- Published
- 2022
30. Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)—Rationale and Design
- Author
-
Derek L. Tran, Hannah Gibson, Andrew J. Maiorana, Charlotte E. Verrall, David W. Baker, Melanie Clode, David R. Lubans, Diana Zannino, Andrew Bullock, Suzie Ferrie, Julie Briody, Peter Simm, Vishva Wijesekera, Michelle D'Almeida, Sally E. Gosbell, Glen M. Davis, Robert Weintraub, Anthony C. Keech, Rajesh Puranik, Martin Ugander, Robert Justo, Dominica Zentner, Avik Majumdar, Leeanne Grigg, Jeff S. Coombes, Yves d'Udekem, Norman R. Morris, Julian Ayer, David S. Celermajer, and Rachael Cordina
- Subjects
cardiac rehabilitation ,aerobic exercise ,single ventricle ,tricuspid atresia ,telehealth ,Pediatrics, Perinatology and Child Health ,hypoplastic left heart syndrome ,Review ,exercise intolerance ,Pediatrics ,congenital heart disease ,RJ1-570 - Abstract
Background: Despite developments in surgical techniques and medical care, people with a Fontan circulation still experience long-term complications; non-invasive therapies to optimize the circulation have not been established. Exercise intolerance affects the majority of the population and is associated with worse prognosis. Historically, people living with a Fontan circulation were advised to avoid physical activity, but a small number of heterogenous, predominantly uncontrolled studies have shown that exercise training is safe—and for unique reasons, may even be of heightened importance in the setting of Fontan physiology. The mechanisms underlying improvements in aerobic exercise capacity and the effects of exercise training on circulatory and end-organ function remain incompletely understood. Furthermore, the optimal methods of exercise prescription are poorly characterized. This highlights the need for large, well-designed, multi-center, randomized, controlled trials.Aims and Methods: The Fontan Fitness Intervention Trial (F-FIT)—a phase III clinical trial—aims to optimize exercise prescription and delivery in people with a Fontan circulation. In this multi-center, randomized, controlled study, eligible Fontan participants will be randomized to either a 4-month supervised aerobic and resistance exercise training program of moderate-to-vigorous intensity followed by an 8-month maintenance phase; or usual care (control group). Adolescent and adult (≥16 years) Fontan participants will be randomized to either traditional face-to-face exercise training, telehealth exercise training, or usual care in a three-arm trial with an allocation of 2:2:1 (traditional:telehealth:control). Children (
- Published
- 2022
31. Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study
- Author
-
Russell S. Scott, Anthony C Keech, Gregory R. Fulcher, Stephen Colagiuri, Emma S. Scott, Andrzej S. Januszewski, Rachel O'Connell, Linda Wu, Alicia J. Jenkins, and Antero Kesäniemi
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Coefficient of variation ,Clinical Biochemistry ,Type 2 diabetes ,Diabetic angiopathy ,Biochemistry ,Gastroenterology ,Endocrinology ,Diabetes mellitus ,Internal medicine ,Post-hoc analysis ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Stroke ,Finland ,Aged ,Glycemic ,Glycated Hemoglobin ,Biological Variation, Individual ,business.industry ,Biochemistry (medical) ,Australia ,Fasting ,Middle Aged ,medicine.disease ,Diabetes Mellitus, Type 2 ,Female ,business ,Diabetic Angiopathies ,New Zealand - Abstract
Aims To investigate whether long-term glycemic variability (GV) is associated with vascular complication development in type 2 diabetes. Methods In a post hoc FIELD trial analysis, GV was calculated as the standard deviation and coefficient of variation (CV) of glycated hemoglobin A1c (HbA1c) and fasting plasma glucose. Baseline variables were compared across quartiles of on-study variability by chi square and ANOVA. Prospective associations between baseline to 2-year GV and subsequent vascular and mortality outcomes were analyzed using landmark logistic and Cox proportional hazards regression. Results Baseline factors associated with higher on-study GV included younger age, male gender, longer diabetes duration, and higher pharmacological therapies usage. Both HbA1c and fasting glucose CV were associated with increased risk of microvascular complications (HR 1.02 [95% CI, 1.01-1.03] P < 0.01; and HR 1.01 [95% CI, 1.00-1.01] P < 0.001, respectively). HbA1c and fasting glucose CV were associated with increased cardiovascular disease (HR 1.02 [95% CI, 1.00-1.04]; and HR 1.01 [95% CI, 1.00-1.02], both P < 0.05). HbA1c CV associated with increased stroke (HR 1.03 [95% CI, 1.01-1.06) P < 0.01). Glucose CV associated with increased coronary events (HR 1.01 [95% CI, 1.00-1.02] P < 0.05). Both HbA1c and glucose CV associated with increased total mortality (HR 1.04 [95% CI, 1.02-1.06]; and HR 1.01 [95% CI, 1.01-1.02], both P < 0.001) and noncardiovascular mortality (HR 1.05 [95% CI, (1.03-1.07]; and HR 1.02 [95% CI, 1.01-1.03], both P < 0.001). HbA1c CV associated with coronary mortality (HR 1.04 [95% CI, 1.01-1.07] P < 0.05). Conclusions Long-term GV was associated with increased risk of vascular outcomes in type 2 diabetes.
- Published
- 2020
32. The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial
- Author
-
Neena Modi, K. Cornthwaite, Kei Lui, Brian A Darlow, P. Koorts, Girish Deshpande, Rebecca L. Brown, Kristy P. Robledo, E. Noble, Margaret Broom, David Isaacs, Deborah Schofield, Tim Schindler, R. Tobiansky, D. Darcy, W. Nie, Ian C. Marschner, Mohamed E Abdel-Latif, P. Kwan, John Sinn, Anthony C Keech, Javeed Travadi, A. Lewis, A. Bhaskaracharya, Paolo Manzoni, Nicola C. Austin, Louise Goodchild, Kelly M. Dixon, Scott Morris, L. McKeown, E. Yeomans, Anu Kochar, Lisa M. Askie, C. Hua, Andrew J. Martin, William Tarnow-Mordi, David A Osborn, Clare L. Collins, Neil Marlow, Harshad Patel, David Espinoza, Wendy Hague, Patricia Graham, R. John Simes, Mohan Pammi, Mark Tracy, Melinda Cruz, B. Stenson, Margo Pritchard, Alpana Ghadge, Murray Hinder, Sacha Reid, Adrienne Gordon, Roger Soll, Helen G. Liley, Christopher J. D. McKinlay, Joanna Michalowski, R. Black, and N Wilkes
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Critical Care ,Databases, Factual ,Population ,law.invention ,Sepsis ,Double-Blind Method ,Randomized controlled trial ,law ,Cause of Death ,Intensive Care Units, Neonatal ,Intensive care ,Developmental and Educational Psychology ,medicine ,Humans ,Infant, Very Low Birth Weight ,Lactoferrin ,Dietary Supplements ,Hospital Mortality ,education ,Cause of death ,education.field_of_study ,biology ,business.industry ,Very Low Birth Weight ,Australia ,Infant, Newborn ,Infant ,medicine.disease ,Survival Analysis ,Clinical trial ,Relative risk ,Pediatrics, Perinatology and Child Health ,biology.protein ,Female ,Morbidity ,business ,New Zealand - Abstract
Summary Background Very low birthweight or preterm infants are at increased risk of adverse outcomes including sepsis, necrotising enterocolitis, and death. We assessed whether supplementing the enteral diet of very low-birthweight infants with lactoferrin, an antimicrobial protein, reduces all-cause mortality or major morbidity. Methods We did a multicentre, double-blind, pragmatic, randomised superiority trial in 14 Australian and two New Zealand neonatal intensive care units. Infants born weighing less than 1500 g and aged less than 8 days, were eligible and randomly assigned (1:1) using minimising web-based randomisation to receive once daily 200 mg/kg pasteurised bovine lactoferrin supplements or no lactoferrin supplement added to breast or formula milk until 34 weeks' post-menstrual age (or for 2 weeks, if longer), or until discharge from the study hospital if that occurred first. Designated nurses preparing the daily feeds were not masked to group assignment, but other nurses, doctors, parents, caregivers, and investigators were unaware. The primary outcome was survival to hospital discharge or major morbidity (defined as brain injury, necrotising enterocolitis, late-onset sepsis at 36 weeks' post-menstrual age, or retinopathy treated before discharge) assessed in the intention-to-treat population. Safety analyses were by treatment received. We also did a prespecified, PRISMA-compliant meta-analysis, which included this study and other relevant randomised controlled trials, to estimate more precisely the effects of lactoferrin supplementation on late-onset sepsis, necrotising enterocolitis, and survival. This trial is registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12611000247976. Findings Between June 27, 2014, and Sept 1, 2017, we recruited 1542 infants; 771 were assigned to the intervention group and 771 to the control group. One infant who had consent withdrawn before beginning lactoferrin treatment was excluded from analysis. In-hospital death or major morbidity occurred in 162 (21%) of 770 infants in the intervention group and in 170 (22%) of 771 infants in the control group (relative risk [RR] 0·95, 95% CI 0·79–1·14; p=0·60). Three suspected unexpected serious adverse reactions occurred; two in the lactoferrin group, namely unexplained late jaundice and inspissated milk syndrome, but were not attributed to the intervention and one in the control group had fatal inspissated milk syndrome. Our meta-analysis identified 13 trials completed before Feb 18, 2020, including this Article, in 5609 preterm infants. Lactoferrin supplements significantly reduced late-onset sepsis (RR 0·79, 95% CI 0·71–0·88; p Interpretation Lactoferrin supplementation did not improve death or major morbidity in this trial, but might reduce late-onset sepsis, as found in our meta-analysis of over 5000 infants. Future collaborative studies should use products with demonstrated biological activity, be large enough to detect moderate and clinically important effects reliably, and assess greater doses of lactoferrin in infants at increased risk, such as those not exclusively receiving breastmilk or infants of extremely low birthweight. Funding Australian National Health and Medical Research Council.
- Published
- 2020
33. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- Author
-
Christian T. Ruff, Anthony C Keech, Nicholas A Marston, Robert P. Giugliano, Giorgio E. M. Melloni, Marc S. Sabatine, Terje R. Pedersen, Yared Gurmu, Peter S. Sever, Baris Gencer, Marc P. Bonaca, Carolina Roselli, Patrick T. Ellinor, Michelle L. O'Donoghue, and Steven A. Lubitz
- Subjects
medicine.medical_specialty ,numbers needed to treat ,venous thromboembolism ,030204 cardiovascular system & hematology ,THERAPY ,LDL ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Physiology (medical) ,Internal medicine ,medicine ,PCSK9 protein ,STATINS ,LIPOPROTEIN(A) ,cardiovascular diseases ,human ,ROSUVASTATIN ,METAANALYSIS ,030304 developmental biology ,Ldl cholesterol ,0303 health sciences ,Cholesterol ,business.industry ,PCSK9 ,Subtilisin ,cholesterol ,Proprotein convertase ,PREVENTION ,Evolocumab ,Endocrinology ,chemistry ,evolocumab ,ATHEROSCLEROSIS ,Kexin ,Cardiology and Cardiovascular Medicine ,business ,Venous thromboembolism - Abstract
Background: The relationship between cholesterol levels and risk of venous thromboembolism (VTE) is uncertain. We set out to determine the effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of VTE, explore potential mechanisms, and examine the efficacy in subgroups with clinically and genetically defined risk. Methods: We performed a post hoc analysis of the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) testing whether evolocumab reduces the risk of VTE events (deep venous thrombosis or pulmonary embolism). Data from FOURIER and ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab) were then combined in a meta-analysis to assess the class effect of PCSK9 inhibition on the risk of VTE. We also analyzed baseline lipids in FOURIER to investigate potential mechanisms explaining the reduction in VTE with evolocumab. Last, an exploratory genetic analysis was performed in FOURIER to determine whether a VTE polygenic risk score could identify high-risk patients who would derive the greatest VTE reduction from evolocumab. Results: In FOURIER, the hazard ratio (HR) for VTE with evolocumab was 0.71 (95% CI, 0.50–1.00; P =0.05), with no effect in the 1st year (HR, 0.96 [95% CI, 0.57–1.62]) but a 46% reduction (HR, 0.54 [95% CI, 0.33–0.88]; P =0.014) beyond 1 year. A meta-analysis of FOURIER and ODYSSEY OUTCOMES demonstrated a 31% relative risk reduction in VTE with PCSK9 inhibition (HR, 0.69 [95% CI, 0.53–0.90]; P =0.007). There was no relation between baseline low-density lipoprotein cholesterol levels and magnitude of VTE risk reduction. In contrast, in patients with higher baseline lipoprotein(a) (Lp[a]) levels, evolocumab reduced Lp(a) by 33 nmol/L and risk of VTE by 48% (HR, 0.52 [95% CI, 0.30–0.89]; P =0.017), whereas, in patients with lower baseline Lp(a) levels, evolocumab reduced Lp(a) by only 7 nmol/L and had no effect on VTE risk ( P interaction 0.087 for HR; P heterogeneity 0.037 for absolute risk reduction). Modeled as a continuous variable, there was a significant interaction between baseline Lp(a) concentration and magnitude of VTE risk reduction ( P interaction =0.04). A polygenic risk score identified patients who were at >2-fold increased risk for VTE and who derived greater relative ( P interaction =0.04) and absolute VTE reduction ( P heterogeneity =0.009) in comparison with those without high genetic risk. Conclusions: PCSK9 inhibition significantly reduces the risk of VTE. Lp(a) reduction may be an important mediator of this effect, a finding of particular interest given the ongoing development of potent Lp(a) inhibitors.
- Published
- 2020
34. Cognition After Lowering LDL-Cholesterol With Evolocumab
- Author
-
Brian R. Ott, Fourier Investigators, Marc S. Sabatine, KyungAh Im, Huei Wang, Jianping Guo, Baris Gencer, Anthony C Keech, Christopher E. Kurtz, Terje R. Pedersen, Robert P. Giugliano, François Mach, and Andrea Ruzza
- Subjects
Adult ,Male ,medicine.medical_specialty ,Statin ,medicine.drug_class ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,Placebo ,03 medical and health sciences ,chemistry.chemical_compound ,Cognition ,0302 clinical medicine ,Double-Blind Method ,Internal medicine ,medicine ,Humans ,Cognitive Dysfunction ,030212 general & internal medicine ,Effects of sleep deprivation on cognitive performance ,Cognitive decline ,Aged ,Aged, 80 and over ,business.industry ,Cholesterol ,Anticholesteremic Agents ,PCSK9 ,Cholesterol, LDL ,Middle Aged ,Atherosclerosis ,Evolocumab ,chemistry ,Cardiovascular Diseases ,Drug Therapy, Combination ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business - Abstract
The EBBINGHAUS (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects) trial demonstrated that evolocumab added to a background statin did not affect cognitive performance in a subset of 1,204 patients enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 inhibitors in Subjects With Elevated Risk).The authors describe patient-reported cognition in the entire FOURIER trial using a self-survey.FOURIER was a randomized, double-blind, placebo-controlled trial involving patients with atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels ≥70 mg/dl or non-high-density cholesterol ≥100 mg/dl despite statin therapy. At the final visit, patients completed a 23-item survey on memory and executive domains from the Everyday Cognition (ECog) scale. Patients compared their levels of everyday function at the end of the trial with their levels at the beginning and scored as 1 (no change or improvement), 2 (occasionally worse), 3 (consistently little worse), or 4 (consistently much worse). ECog scores were compared by the 2 randomized treatment arms and by achieved LDL-C at 4 weeks.A total of 22,655 patients completed ECog after a median duration of 2.2 years. The proportions of patients reporting cognitive decline (ECog score ≥2) at the end of the study were similar for placebo versus evolocumab, both for total score 3.6% versus 3.7% (p = 0.62) and for subdomains (memory, 5.8% vs. 6.0%; total executive, 3.6% vs. 3.7%). The proportion of patients reporting a decline in total cognitive score was similar among the 2,338 patients who achieved very low LDL-C levels (20 mg/dl) compared to the 3,613 patients with LDL-C ≥100 mg/dl (3.8% vs. 4.5%, p = 0.57).The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients who achieved LDL-C 20 mg/dl.
- Published
- 2020
35. Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score Results From the FOURIER Trial
- Author
-
Marc S. Sabatine, Huei Wang, Terje R. Pedersen, Frederick K. Kamanu, Anthony C Keech, Yared Gurmu, Francesco Nordio, Nicholas A Marston, Steven A. Lubitz, Carolina Roselli, Christian T. Ruff, Robert P. Giugliano, Patrick T. Ellinor, Peter S. Sever, and Armando Lira Pineda
- Subjects
Oncology ,medicine.medical_specialty ,Multifactorial Inheritance ,Disease ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Antibodies, Monoclonal, Humanized ,Article ,03 medical and health sciences ,0302 clinical medicine ,cardiovascular disease ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,PCSK9 protein ,risk factors ,In patient ,genetics ,CORONARY-HEART-DISEASE ,human ,Genetic risk ,METAANALYSIS ,030304 developmental biology ,0303 health sciences ,business.industry ,PCSK9 ,Atherosclerotic disease ,Antibodies, Monoclonal ,Proprotein convertase ,Evolocumab ,evolocumab ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been established. Methods: We studied 14 298 patients with atherosclerotic cardiovascular disease from the FOURIER trial (Further Cardiovascular Outcomes Researh With PCSK9 Inhibition in Subjects With Elevated Risk). A 27–single-nucleotide polymorphism genetic risk score defined low (quintile 1), intermediate (quintiles 2–4), and high (quintile 5) genetic risk. Patients were also categorized by major atherosclerotic risk factors including diabetes mellitus, hypertension, low-density lipoprotein cholesterol ≥100 mg/dl, and smoking; multiple (≥2) risk factors was considered high clinical risk. Outcomes consisted of major coronary events (coronary heart death, myocardial infarction, or coronary revascularization) and major vascular events (major coronary events and ischemic stroke). Median follow-up was 2.3 years. Results: After we adjusted for clinical factors, the genetic risk score was associated with risk for both major vascular events ( P trend =0.005) and major coronary events ( P trend P =0.86). In contrast, there was a 13% relative risk reduction (HR, 0.87 [0.75–0.998], P =0.047) and a 1.4% ARR in patients with multiple clinical risk factors but without high genetic risk and a 31% relative risk reduction (HR, 0.69 [0.55–0.86], P =0.0012), and 4.0% ARR in patients with high genetic risk, irrespective of clinical risk ( P trend for HR=0.017, ARR P trend =0.004). Patients with high genetic risk who received evolocumab had event rates similar to patients with a low burden of both genetic and clinical risk. Conclusion: Patients without multiple clinical risk factors or high genetic risk had a low event rate and did not appear to derive benefit from evolocumab over 2.3 years. Conversely, patients with multiple clinical risk factors but without high genetic risk had intermediate risk and intermediate risk reduction. Patients with high genetic risk, regardless of clinical risk, had a high event rate and derived the greatest relative and absolute benefit from evolocumab, which mitigated this risk.
- Published
- 2020
36. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
- Author
-
Laura Park, Ian Wilcox, Gian Luca Di Tanna, Nishan Abeysuriya, Jordan Fulcher, Anthony Rodgers, Sean Lal, Anthony C Keech, Shejil Kumar, and Nelson Wang
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,MEDLINE ,chemistry.chemical_compound ,Endocrinology ,Ezetimibe ,Risk Factors ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,Humans ,Myocardial infarction ,Cholesterol ,business.industry ,Anticholesteremic Agents ,Cholesterol, LDL ,Atherosclerosis ,medicine.disease ,Treatment Outcome ,chemistry ,Cardiovascular Diseases ,Meta-analysis ,Relative risk ,lipids (amino acids, peptides, and proteins) ,business ,medicine.drug ,Kidney disease - Abstract
The benefits of LDL cholesterol-lowering treatment for the prevention of atherosclerotic cardiovascular disease are well established. However, the extent to which these effects differ by baseline LDL cholesterol, atherosclerotic cardiovascular disease risk, and the presence of comorbidities remains uncertain.We did a systematic literature search (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, from inception up to June 15, 2019) for randomised controlled trials of statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors with at least 1000 patient-years of follow-up. Random-effects meta-analysis and meta-regressions were done to assess for risk of major vascular events (a composite of cardiovascular mortality, non-fatal myocardial infarction, non-fatal ischaemic stroke, or coronary revascularisation) per 1 mmol/L (38·7 mg/dL) reduction in LDL cholesterol concentrations.327 037 patients from 52 studies were included in the meta-analysis. Each 1 mmol/L reduction in LDL cholesterol was associated with a 19% relative risk (RR) reduction for major vascular events (RR 0·81 [95% CI 0·78-0·84]; p0·0001). Similar reductions (per 1 mmol/L reduction in LDL cholesterol) were found in trials with participants with LDL cholesterol 2·60 mmol/L or lower, 2·61-3·40 mmol/L, 3·41-4·10 mmol/L, and more than 4·1 mmol/L (p=0·232 for interaction); and in a subgroup of patients who all had a baseline LDL cholesterol less than 2·07 mmol/L (80 mg/dL; RR 0·83 [95% CI 0·75-0·92]; p=0·001). We found greater RR reductions in patients at lower 10-year atherosclerotic cardiovascular disease risk (change in RR per 10% lower 10-year atherosclerotic cardiovascular disease 0·97 [95% CI 0·95-0·98]; p0·0001) and in patients at younger age across a mean age of 50-75 years (change in RR per 10 years younger age 0·92 [0·83-0·97]; p=0·015). We found no difference in RR reduction for participants with or without diabetes (p=0·878 for interaction) and chronic kidney disease (p=0·934 for interaction).For each 1 mmol/L LDL cholesterol lowering, the risk reduction of major vascular events is independent of the starting LDL cholesterol or the presence of diabetes or chronic kidney disease. Patients at lower cardiovascular risk and younger age might have a similar relative reduction in risk with LDL-cholesterol lowering therapies and future studies should investigate the potential benefits of earlier intervention.None.
- Published
- 2020
37. Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy
- Author
-
Nicola, Quinn, Andrzej S, Januszewski, Laima, Brazionis, Rachel, O'Connell, Nanda, Aryal, Justin, O'Day, Russell, Scott, Paul, Mitchell, Alicia J, Jenkins, and Anthony C, Keech
- Subjects
Diabetic Retinopathy ,Diabetes Mellitus, Type 2 ,Fenofibrate ,Venules ,Humans ,Retinal Vessels - Abstract
Retinal vessel calibre metrics were evaluated at baseline and 2 years in a FIELD substudy (n = 208). Central retinal venule calibre was significantly reduced by fenofibrate and unchanged by placebo. Arteriole metrics did not change. Larger studies relating retinal vessel calibre to future diabetes complications and response to therapy are merited.
- Published
- 2021
38. Abstract 13846: Prognostic Value of Echocardiographic Markers of Diastolic Dysfunction for Heart Failure in Overweight and Obese Patients in CAMELLIA-TIMI 61
- Author
-
Jingyi Gong, Benjamin M Scirica, Neil J Weissman, Minao Tang, Silvio E Inzucchi, Darren K McGuire, Anthony C Keech, Stephen D Wiviott, Marc S Sabatine, and Erin Bohula
- Subjects
Physiology (medical) ,Cardiology and Cardiovascular Medicine - Abstract
Background: Recent guidelines have outlined echo markers of diastolic dysfunction (DD); evidence is limited for their prognostic value for hospitalization for heart failure (HHF) in overweight and obese pts. Methods: CAMELLIA-TIMI 61 was a randomized placebo-controlled trial of the weight loss agent lorcaserin in 12,000 pts with BMI ≥27 with or at risk for CV disease (median follow-up, 3.3 yrs). Echo with core lab interpretation was performed on a subset of pts. Established DD parameters were measured, including the ratio of the peak early transmitral diastolic flow velocity over the early diastolic mitral annulus velocity (average E/e’), left atrium volume index (LAVi), and tricuspid regurgitation jet velocity (TRV). These were analyzed continuously, using the standard cutpoints of >14, >34 mL/m 2 , and >2.8 m/s, respectively, and separately to determine the optimal cutpoints. The primary outcome for this analysis was HHF. Results: In 3,972 pts with baseline ejection fraction ≥50%, all 3 variables on a continuous scale predicted increased risk of HHF; using standard cutpoints, only E/e’>14 remained independently associated with HHF after adjustment for the other 2 echo parameters and clinical variables ( Panel A ). In an analysis of optimal cutpoints in these overweight and obese pts, >13 was optimal for E/e’, >2.5 m/s for TRV, and >58 mL/m 2 for LAVi. In a model with all 3 echo parameters, all remained significant predictors of HHF. After incorporation of clinical variables, E/e’ (HR 2.15, 95%CI 1.24-3.72) and LAVi (HR 2.41, 1.33-4.36) remained independent predictors of HHF ( Panel A ). Rates of HHF were 0.6, 3.3, and 10.1% (p-trendPanel B ). Conclusions: Several echocardiographic markers of diastolic dysfunction used in current guidelines predict increased risk of HHF events in the understudied obese and overweight population. A higher LAVi (> 58 ml/m 2 ) cutpoint should be considered in these pts to prognosticate risk of HHF.
- Published
- 2021
39. Prevalence of diabetic retinopathy and reduced vision among indigenous Australians in the nurse-led integrated Diabetes Education and Eye Screening study in a regional primary care clinic
- Author
-
Alicia J. Jenkins, Chris Ryan, Sharon Atkinson-Briggs, Laima Brazionis, and Anthony C Keech
- Subjects
medicine.medical_specialty ,Reduced vision ,business.industry ,Type 2 diabetes ,Diabetic retinopathy ,medicine.disease ,Primary care clinic ,Indigenous ,Nurse led ,Diabetes mellitus ,Family medicine ,Internal Medicine ,medicine ,Grading (education) ,business - Abstract
Nationally, Indigenous Australians are more likely to have diabetes and diabetic retinopathy (DR) than non-Indigenous Australians. However, the prevalence of DR and impaired vision in regional primary care settings is unclear.To describe the prevalence and severity of DR and presenting vision level among Indigenous Australian adults with diabetes attending an indigenous primary care clinic in regional Australia.Participants underwent nurse-led retinal imaging and DR screening with offsite retinal grading in the integrated Diabetes Education and Eye Screening (iDEES) project implemented at a regional indigenous primary healthcare setting between January 2018 and March 2020.Of 172 eligible adults, 135 (79%) were recruited and screened for DR and vision level. The median age was 56 (46-67) years, 130 (96%) had type 2 diabetes of median (interquartile range) duration 6 (2-12) years and 48 (36%) were male. Images from 132 (97.8%) participants were gradable. DR was present in 38 (29%) participants: mild non-proliferative in 33 (25%); moderate-severe in three (2.5%); and sight-threatening two (1.5%). Subnormal presenting vision was present in 33%.A nurse-led model of care integrating diabetes eye screening and education at a single visit was successful at recruiting Indigenous Australian adults with diabetes, screening their vision and acquiring a high rate of gradable images. Even for a short duration of known diabetes, DR was present in three out of 10 patients screened.
- Published
- 2021
40. Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes: A Randomized Clinical Trial
- Author
-
Grant J. Smith, Martin de Bock, Sybil A McAuley, Anthony C Keech, Alicia J. Jenkins, Timothy W. Jones, Bruce R. King, Julie Dart, Mary B Abraham, Fergus J. Cameron, Janice M Fairchild, Elizabeth A. Davis, David N O'Neal, and Geoffrey R Ambler
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Glycemic Control ,Hypoglycemia ,law.invention ,Quality of life ,Randomized controlled trial ,law ,Diabetes mellitus ,Internal medicine ,Outcome Assessment, Health Care ,medicine ,Humans ,Child ,Glycemic ,Original Investigation ,Type 1 diabetes ,business.industry ,Insulin ,medicine.disease ,Psychosocial Functioning ,Clinical research ,Diabetes Mellitus, Type 1 ,Pediatrics, Perinatology and Child Health ,Female ,business - Abstract
IMPORTANCE: Hybrid closed-loop (HCL) therapy has improved glycemic control in children and adolescents with type 1 diabetes; however, the efficacy of HCL on glycemic and psychosocial outcomes has not yet been established in a long-term randomized clinical trial. OBJECTIVE: To determine the percentage of time spent in the target glucose range using HCL vs current conventional therapies of continuous subcutaneous insulin infusion or multiple daily insulin injections with or without continuous glucose monitoring (CGM). DESIGN, SETTING, AND PARTICIPANTS: This 6-month, multicenter, randomized clinical trial included 172 children and adolescents with type 1 diabetes; patients were recruited between April 18, 2017, and October 4, 2019, in Australia. Data were analyzed from July 25, 2020, to February 26, 2021. INTERVENTIONS: Eligible participants were randomly assigned to either the control group for conventional therapy (continuous subcutaneous insulin infusion or multiple daily insulin injections with or without CGM) or the intervention group for HCL therapy. MAIN OUTCOMES AND MEASURES: The primary outcome was the percentage of time in range (TIR) within a glucose range of 70 to 180 mg/dL, measured by 3-week masked CGM collected at the end of the study in both groups. Secondary outcomes included CGM metrics for hypoglycemia, hyperglycemia, and glycemic variability and psychosocial measures collected by validated questionnaires. RESULTS: A total of 135 patients (mean [SD] age, 15.3 [3.1] years; 76 girls [56%]) were included, with 68 randomized to the control group and 67 to the HCL group. Patients had a mean (SD) diabetes duration of 7.7 (4.3) years and mean hemoglobin A(1c) of 64 (11) mmol/mol, with 110 participants (81%) receiving continuous subcutaneous insulin infusion and 72 (53%) receiving CGM. In the intention-to-treat analyses, TIR increased from a mean (SD) of 53.1% (13.0%) at baseline to 62.5% (12.0%) at the end of the study in the HCL group and from 54.6% (12.5%) to 56.1% (12.2%) in the control group, with a mean adjusted difference between the 2 groups of 6.7% (95% CI, 2.7%-10.8%; P = .002). Hybrid closed-loop therapy also reduced the time that patients spent in a hypoglycemic (
- Published
- 2021
41. A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts
- Author
-
Rory Collins, Borislava Mihaylova, J Zhou, Jane Armitage, Iryna Schlackow, Anthony C Keech, Jonathan Emberson, Christina Reith, John Robson, John Simes, K Wilkinson, Alastair Gray, Colin Baigent, R Wu, and C Williams
- Subjects
Clinical trial ,medicine.medical_specialty ,business.industry ,medicine ,Disease ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business ,Health outcomes - Abstract
Background and purpose Cardiovascular disease (CVD) risk of individuals depends on their socio-demographic characteristics, clinical risk factors, and treatments, and strongly influences their quality of life and survival. Individual-based long-term disease models, which aim to more accurately calculate the lifetime consequences, can help to target treatments, develop disease management programmes, and assess the value of new therapies. We present a new micro-simulation CVD model. Methods This micro-simulation model was developed using individual participant data from the Cholesterol Treatment Trialists' collaboration (CTT: 118,000 participants; 15 trials) and calibrated (with added socioeconomic deprivation, ethnicity, physical activity, mental illness, cancer and incident diabetes) in the UK Biobank cohort (UKB: 502,000 participants). Parametric survival models estimated risks of key endpoints (myocardial infarction (MI), stroke, coronary revascularisation (CRV), diabetes, cancer and vascular (VD) and nonvascular death (NVD) using participants' age, sex, ethnicity, physical activity, socioeconomic deprivation, smoking history, lipids, blood pressure, creatinine, previous cardiovascular diseases, diabetes, mental illness and cancer at entry and non-fatal incidents of the key endpoints during follow-up. The model integrates the risk equations and enables annual projection of endpoints and survival over individuals' lifetimes. The model was used to project remaining life expectancy across UK Biobank participants. Results Nonfatal cardiovascular events and age were the major determinants of CVD risk and, together with incident diabetes and cancer, of individuals' survival. The cumulative incidence of the key endpoints predicted by the CTT-UKB model corresponded well to their observed incidence in the UK Biobank cohort, overall (Figure 1) and in categories of participants by age, sex, prior CVD and CVD risk. Predicted remaining life expectancy across UK Biobank participants without history of CVD ranged between 22 and 43 years in men and between 24 and 46 years in women, depending on their age and CVD risk (Figure 2). Among UK Biobank participants with history of CVD, depending on their age, predicted remaining life expectancy ranged from 20 to 32 years in men and from 26 to 38 years in women. Conclusion This new lifetime CVD model accurately predicts morbidity and mortality in a large UK population cohort. It will be made available to provide individualised projections of expected lifetime health outcomes and benefits of treatments. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, UK Medical Research Council (MRC), British Heart Foundation Figure 1. Predicted (in black) versus observed (95% CI; in red) incidence of major clinical outcomes in the UK Biobank.Figure 2. Predicted remaining life expectancy of participants in UK Biobank cohort, by age and CVD risk or previous CVD at entry. QRISK, a 10-year CVD risk scoring algorithm for people without previous CVD, recommended for use in the UK National Health Service.
- Published
- 2021
42. Novel pressure-regulated deployment strategy for improving the safety and efficacy of balloon-expandable transcatheter aortic valves
- Author
-
Michael K. Wilson, David S. Celermajer, Anthony C Keech, Sophia Wong, A. Snir, Christopher Naoum, K. Wong, A L Ju, K. Khor, and Martin K.C. Ng
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Balloon expandable stent ,Transcatheter aortic ,Software deployment ,business.industry ,medicine ,Cardiology and Cardiovascular Medicine ,business ,Surgery - Abstract
Background The optimal method for balloon-expandable transcatheter heart valve (THV) deployment remains unknown. Current implantation protocols are volume-dependent and rely on ad-hoc filling of the deployment apparatus without accounting for annular wall tension during prosthesis expansion, predisposing patients to inconsistent clinical outcomes. During THV deployment, the annular wall tension exerted by the expanding prosthesis is determined by prosthesis diameter and balloon pressure (Laplace's Law). Objective We proposed and tested a novel method for balloon-expandable THV deployment, aimed at controlling balloon pressure and the resulting annular wall tension to allow optimal prosthesis-annulus apposition while preventing significant tissue injury. Methods 330 consecutive patients with severe native aortic stenosis who underwent balloon-expandable THV implantation between 2015–2020 were included. 106 patients were considered high-risk for annular rupture. THVs were deployed until reaching a pre-determined balloon pressure; 4–4.5atm in earlier cases to establish experience and safety, later increasing to 5–6.5atm in most cases. Post-dilatation was performed to reduce >mild angiographic regurgitation (PVR). Using a biomechanical model, annular wall stress (tension) was estimated for each case and assessed against recorded rates of post-dilatation, ≥mild paravalvular regurgitation (PVR) on TTE, new PPM or LBBB and annular rupture. Results Patients with wall stress >3MPa (n=184) had reduced post-dilatation rate (p3.5MPa; no rupture occurred in 102 high-risk cases with wall stress ≤3.5MPa. Based on these results, we defined target deployment wall stress levels (3–3.5MPa) and associated deployment pressure per THV size. Patients within this target range (n=136) had 8.1% new PPM, 12.5% new LBBB, 12.7% mild PVR with no cases of ≥moderate PVR. Importantly, there was an inconsistent relationship between deployment balloon volume and resulting annular wall stress. Conclusion Pressure-regulated THV deployment is a simple, easily reproducible, safe and effective method, regardless of high-risk anatomical complexities. Funding Acknowledgement Type of funding sources: None. Annular wall stress and PVRModel, stress vs volume and new strategy
- Published
- 2021
43. Cardiovascular benefit of lowering LDL-C below 1 mmol/L (40 mg/dl)
- Author
-
Anthony C Keech, Marc S. Sabatine, Andrea Ruzza, Nicholas A Marston, Robert P. Giugliano, Peter S. Sever, and Jeong-Gun Park
- Subjects
business.industry ,Mole ,Medicine ,lipids (amino acids, peptides, and proteins) ,Pharmacology ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background The 2019 ESC/EAS Dyslipidemia Guidelines recommend an LDL-C goal of Methods FOURIER was a cardiovascular outcomes trial comparing evolocumab vs. placebo in patients with stable ASCVD on optimized statin therapy with a median follow-up of 2.2 years. We performed an exploratory analysis to determine the consistency of CV risk reduction with LDL-C lowering below ∼1 mmol/L (40 mg/dl) with evolocumab. We modeled the achieved LDL-C at 48 weeks in the two treatment arms as well as the percentage of LDL-C difference between the two arms that was due to LDL-C below ∼1 mmol/L (40 mg/dl) as a function of baseline LDL-C. We then modeled the hazard ratio (HR) for the composite of CV death, MI or stroke (per 1 mmol/L reduction in LDL-C) with evolocumab vs. placebo as a function of baseline LDL-C. Results All 27,564 patients from FOURIER were included in this analysis. Patients with lower baseline LDL-C achieved lower LDL-C levels following evolocumab therapy, with achieved LDL-C typically being below 1 mmol/L (40 mg/dl) once the baseline LDL-C was below 2.4 mmol/L (94 mg/dl) and reaching levels approaching 0.5 mmol/L (∼20 mg/dl). Accordingly, the further baseline LDL-C levels were below 2.4 mmol/L (94 mg/dl), the greater the proportion of the difference in achieved LDL-C between the evolocumab and placebo arms was due to LDL-C levels below ∼1 mmol/L (40 mg/dl), reaching nearly 40% of the difference in LDL-C between treatment arms (Upper Panel). Despite this, the clinical benefit of LDL-C lowering was not attenuated (p=0.78) (and even appeared greater), with robust reductions in risk of CV death, MI or stroke even when LDL-C was lowered to nearly 0.5 mmol/L (∼20 mg/dl) and having close to 40% of the LDL-C difference between treatment arms due to LDL-C lowering below ∼1 mmol/L (40 mg/dl) (Lower Panel). Conclusion PCSK9 inhibitors added to statin therapy can achieve LDL-C well below 1 mmol/L (40 mg/dl). There is no evidence for attenuation of the clinical benefit of lowering LDL-C below this threshold. These data support lowering LDL-C to below 1 mmol/L (40 mg/dl) in patients with ASCVD. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Institute of Health
- Published
- 2021
44. Protocol for the Stimulating β
- Author
-
Kristen J, Bubb, Jason A, Harmer, Meghan, Finemore, Sarah Joy, Aitken, Zara S, Ali, Laurent, Billot, Clara, Chow, Jonathan, Golledge, Rebecca, Mister, Michael P, Gray, Stuart M, Grieve, Naomi, Hamburg, Anthony C, Keech, Sanjay, Patel, Vikram, Puttaswamy, and Gemma A, Figtree
- Subjects
clinical trials ,Walking ,vascular medicine ,Physical Functional Performance ,Cardiovascular Medicine ,Peripheral Arterial Disease ,Thiazoles ,Clinical Trials, Phase II as Topic ,Double-Blind Method ,Receptors, Adrenergic, beta-3 ,Quality of Life ,Humans ,Multicenter Studies as Topic ,magnetic resonance imaging ,Acetanilides ,Randomized Controlled Trials as Topic - Abstract
Introduction There is currently only one approved medication effective at improving walking distance in people with intermittent claudication. Preclinical data suggest that the β3-adrenergic receptor agonist (mirabegron) could be repurposed to treat intermittent claudication associated with peripheral artery disease. The aim of the Stimulating β3-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial is to test whether mirabegron improves walking distance in people with intermittent claudication. Methods and analysis The STAR-PAD trial is a Phase II, multicentre, double-blind, randomised, placebo-controlled trial of mirabegron versus placebo on walking distance in patients with PAD. A total of 120 patients aged ≥40 years with stable PAD and intermittent claudication will be randomly assigned (1:1 ratio) to receive either mirabegron (50 mg orally once a day) or matched placebo, for 12 weeks. The primary endpoint is change in peak walking distance as assessed by a graded treadmill test. Secondary endpoints will include: (i) initial claudication distance; (ii) average daily step count and total step count and (iii) functional status and quality of life assessment. Mechanistic substudies will examine potential effects of mirabegron on vascular function, including brachial artery flow-mediate dilatation; MRI assessment of lower limb blood flow, tissue perfusion and arterial stiffness and numbers and angiogenesis potential of endothelial progenitor cells. Given that mirabegron is safe and clinically available for alternative purposes, a positive study is positioned to immediately impact patient care. Ethics and dissemination The STAR-PAD trial is approved by the Northern Sydney Local Health District Human Research Ethics Committee (HREC/18/HAWKE/50). The study results will be published in peer-reviewed medical or scientific journals and presented at scientific meetings, regardless of the study outcomes. Trial registration number ACTRN12619000423112; Results.
- Published
- 2021
45. Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
- Author
-
David R. Sullivan, Marja-Riitta Taskinen, James D. Best, Nanda R. Aryal, Andrzej S. Januszewski, Russell S. Scott, Anthony C Keech, David Chen, Rachel O'Connell, Gerald F. Watts, R. John Simes, Philip J. Barter, Alicia J. Jenkins, Lee Kong Chian School of Medicine (LKCMedicine), Clinicum, Marja-Riitta Taskinen Research Group, HUS Heart and Lung Center, Department of Medicine, CAMM - Research Program for Clinical and Molecular Metabolism, and Research Programs Unit
- Subjects
Male ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Gastroenterology ,SERUM ,MELLITUS ,0302 clinical medicine ,Endocrinology ,Fenofibrate ,Medicine ,Hypolipidemic Agents ,2. Zero hunger ,Univariate analysis ,Multidisciplinary ,AGE-PEPTIDES ,Diabetes ,food and beverages ,Middle Aged ,3. Good health ,Pulse pressure ,Female ,GLYCATION END-PRODUCTS ,medicine.drug ,Adult ,medicine.medical_specialty ,Science ,Renal function ,030209 endocrinology & metabolism ,RETINOPATHY ,ENDPRODUCTS ,Article ,EVENTS ,03 medical and health sciences ,PEOPLE ,Internal medicine ,Diabetes mellitus ,Humans ,Medicine [Science] ,FLUORESCENCE ,ACCUMULATION ,Aged ,Fluorescent Dyes ,business.industry ,medicine.disease ,Molecular Weight ,Blood pressure ,Diabetes Mellitus, Type 2 ,3121 General medicine, internal medicine and other clinical medicine ,business ,Body mass index - Abstract
People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict complications, and are altered by fenofibrate in adults with type 2 diabetes. Plasma LMW-F were quantified at baseline, after six weeks fenofibrate, and one year post-randomisation to fenofibrate or placebo. LMW-F associations with existing and new composite vascular complications were determined, and effects of fenofibrate assessed. LMW-F correlated positively with age, glycated haemoglobin (HbA1c), pulse pressure, kidney dysfunction and inflammation; and negatively with urate, body mass index, oxidative stress and leptin, albeit weakly (r = 0.04-0.16, all p
- Published
- 2021
46. Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial
- Author
-
Peter W. Schofield, Vaughan J. Carr, Don Weatherburn, Dominic Villa, Tony Butler, Andrew Ellis, Alison L Jones, Rodney J. Scott, Philip B. Mitchell, Jocelyn Jones, David Greenberg, Catherine D'Este, Lee Knight, Alison Churchill, Duncan Chappell, Luke Grant, Kay Wilhelm, Stephen Allnutt, Bianca Ton, Anthony C Keech, and Val Gebski
- Subjects
Male ,medicine.medical_specialty ,Native Hawaiian or Other Pacific Islander ,impulse control disorders ,media_common.quotation_subject ,Population ,Anger ,Impulsivity ,Forensic psychiatry ,Sertraline ,mental disorders ,medicine ,Health Services, Indigenous ,Humans ,Multicenter Studies as Topic ,Psychiatry ,education ,media_common ,Randomized Controlled Trials as Topic ,education.field_of_study ,Recidivism ,business.industry ,Aggression ,General Medicine ,Criminals ,Mental health ,forensic psychiatry ,Clinical trial ,Impulsive Behavior ,Medicine ,Public Health ,medicine.symptom ,business - Abstract
IntroductionConsiderable evidence supports an association between poor impulse control (impulsivity) and violent crime. Furthermore, impulsivity and aggression has been associated with reduced levels of serotonergic activity in the brain. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants that aim to regulate brain serotonin concentrations. Several small studies in psychiatric populations have administered SSRIs to impulsive–aggressive individuals, resulting in reduced impulsivity, anger, aggression and depression. However, no clinical trial has been undertaken in a criminal justice population. This protocol describes the design and implementation of the first systematic study of the potential benefits of SSRIs in impulsive–violent offenders who are at high risk of reoffending.Methods and analysisA randomised, double-blinded, multicentre trial to test the clinical efficacy of an SSRI, sertraline hydrochloride, compared with placebo on recidivism and behavioural measures (including impulsivity, anger, aggression, depression and self-reported offending) over 12 months. 460 participants with histories of violence and screening positive for impulsivity are recruited at several local courts and correctional service offices in New South Wales, Australia.Ethics and disseminationResults will be submitted for publication in a peer-reviewed journal. Possible implications of the effectiveness of this pharmacological intervention include economic benefits of reducing prison costs and societal benefits of improving safety. This study has received ethical approval from the University of New South Wales, Aboriginal Health & Medical Research Council, Corrective Services NSW and the NSW Justice Health and Forensic Mental Health Network.Trial registration numberACTRN12613000442707.
- Published
- 2021
47. Protocol for the Stimulating β3-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease
- Author
-
Sarah J. Aitken, Sanjay Patel, Stuart M. Grieve, Jason A. Harmer, Clara K Chow, Rebecca Mister, Anthony C Keech, Michael P Gray, Gemma A. Figtree, Vikram Puttaswamy, Meghan Finemore, Kristen J. Bubb, Jonathan Golledge, Zara S Ali, Naomi M. Hamburg, and Laurent Billot
- Subjects
business.industry ,Placebo-controlled study ,General Medicine ,Placebo ,medicine.disease ,Intermittent claudication ,Clinical trial ,Anesthesia ,medicine.artery ,medicine ,Clinical endpoint ,Arterial stiffness ,Medicine ,medicine.symptom ,Brachial artery ,Mirabegron ,business ,medicine.drug - Abstract
IntroductionThere is currently only one approved medication effective at improving walking distance in people with intermittent claudication. Preclinical data suggest that the β3-adrenergic receptor agonist (mirabegron) could be repurposed to treat intermittent claudication associated with peripheral artery disease. The aim of the Stimulating β3-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial is to test whether mirabegron improves walking distance in people with intermittent claudication.Methods and analysisThe STAR-PAD trial is a Phase II, multicentre, double-blind, randomised, placebo-controlled trial of mirabegron versus placebo on walking distance in patients with PAD. A total of 120 patients aged ≥40 years with stable PAD and intermittent claudication will be randomly assigned (1:1 ratio) to receive either mirabegron (50 mg orally once a day) or matched placebo, for 12 weeks. The primary endpoint is change in peak walking distance as assessed by a graded treadmill test. Secondary endpoints will include: (i) initial claudication distance; (ii) average daily step count and total step count and (iii) functional status and quality of life assessment. Mechanistic substudies will examine potential effects of mirabegron on vascular function, including brachial artery flow-mediate dilatation; MRI assessment of lower limb blood flow, tissue perfusion and arterial stiffness and numbers and angiogenesis potential of endothelial progenitor cells. Given that mirabegron is safe and clinically available for alternative purposes, a positive study is positioned to immediately impact patient care.Ethics and disseminationThe STAR-PAD trial is approved by the Northern Sydney Local Health District Human Research Ethics Committee (HREC/18/HAWKE/50). The study results will be published in peer-reviewed medical or scientific journals and presented at scientific meetings, regardless of the study outcomes.Trial registration numberACTRN12619000423112; Results.
- Published
- 2021
48. Associations with sight-threatening diabetic macular oedema among Indigenous adults with type 2 diabetes attending an Indigenous primary care clinic in remote Australia: a Centre of Research Excellence in Diabetic Retinopathy and Telehealth Eye and Associated Medical Services Network study
- Author
-
John Boffa, Alicia J. Jenkins, Chris Ryan, Sven-Erik Bursell, Alex Brown, Anthony C Keech, Laima Brazionis, and David N O'Neal
- Subjects
vision ,medicine.medical_specialty ,Population ,030209 endocrinology & metabolism ,Type 2 diabetes ,Retina ,Indigenous ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Epidemiology ,medicine ,macula ,education ,education.field_of_study ,business.industry ,public health ,imaging ,Diabetic retinopathy ,RE1-994 ,medicine.disease ,Ophthalmology ,030221 ophthalmology & optometry ,Albuminuria ,epidemiology ,pathology ,telemedicine ,medicine.symptom ,business ,Body mass index ,Kidney disease - Abstract
ObjectiveTo identify factors associated with sight-threatening diabetic macular oedema (STDM) in Indigenous Australians attending an Indigenous primary care clinic in remote Australia.Methods and analysisA cross-sectional study design of retinopathy screening data and routinely-collected clinical data among 236 adult Indigenous participants with type 2 diabetes (35.6% men) set in one Indigenous primary care clinic in remote Australia. The primary outcome variable was STDM assessed from retinal images.ResultsAge (median (range)) was 48 (21–86) years, and known diabetes duration (median (range)) was 8.0 (0–24) years. Prevalence of STDM was high (14.8%) and similar in men and women. STDM was associated with longer diabetes duration (11.7 vs 7.9 years, respectively; p300 mg/mmol) (20.6 vs 5.7%, respectively; p=0.014) and chronic kidney disease (25.7 vs 12.2%, respectively; p=0.035). Some clinical factors differed by sex: anaemia was more prevalent in women. A higher proportion of men were smokers, prescribed statins and had increased albuminuria. Men had higher blood pressure, but lower glycated Haemoglobin A1c (HbA1c) levels and body mass index, than women.ConclusionSTDM prevalence was high and similar in men and women. Markers of renal impairment and longer diabetes duration were associated with STDM in this Indigenous primary care population. Embedded teleretinal screening, known diabetes duration-based risk stratification and targeted interventions may lower the prevalence of STDM in remote Indigenous primary care services.Trial registration numberAustralia and New Zealand Clinical Trials Register: ACTRN 12616000370404.
- Published
- 2021
49. Novel Pressure-Regulated Deployment Strategy for Improving the Safety and Efficacy of Balloon-Expandable Transcatheter Aortic Valves
- Author
-
Martin K.C. Ng, Afik Snir, Anthony C Keech, Lining A. Ju, Yunduo Zhao, Michael K. Wilson, Kirby Wong, Christopher Naoum, Lynn Khor, Sophia Wong, and David S. Celermajer
- Subjects
medicine.medical_specialty ,Transcatheter aortic ,medicine.medical_treatment ,Aortic Valve Insufficiency ,Regurgitation (circulation) ,Balloon ,Prosthesis Design ,Prosthesis ,Transcatheter Aortic Valve Replacement ,Internal medicine ,medicine ,Humans ,Heart valve ,Left bundle branch block ,business.industry ,Aortic Valve Stenosis ,medicine.disease ,Stenosis ,medicine.anatomical_structure ,Balloon expandable stent ,Treatment Outcome ,Aortic Valve ,Heart Valve Prosthesis ,Cardiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
The authors propose a novel pressure-regulated method for balloon-expandable transcatheter heart valve (THV) deployment, aimed at optimizing prosthesis-annulus apposition while preventing significant tissue injury.The optimal method for balloon-expandable THV deployment remains debated. Current protocols are volume dependent, relying on under- and overfilling of the deployment apparatus. During deployment, the annular wall tension exerted by the expanding prosthesis is determined by maximal THV diameter and balloon pressure (Laplace's law).Three hundred thirty consecutive patients with severe native aortic stenosis who underwent TAVR with SAPIEN 3 THVs were included. One hundred and six patients were considered at high risk for annular rupture. THVs were deployed until reaching a predetermined balloon pressure. Postdilatation was performed to reduce mild or greater angiographic paravalvular regurgitation (PVR). Using a biomechanical model, annular wall stress was estimated for each case and assessed against rates of postdilatation, mild or greater PVR on transthoracic echocardiography, new permanent pacemaker placement or left bundle branch block, and annular rupture.Patients with wall stress3 MPa had reduced postdilatation rate (P 0.001) and reduced final PVR (P = 0.014). Annular rupture occurred in 2 of 3 high-risk patients with wall stress3.5 MPa (3.69 and 3.84 MPa); no rupture occurred in 95 high-risk patients with wall stress ≤3.5 MPa. We defined a single target deployment pressure per THV size to ensure deployment within target wall stress levels of 3 to 3.5 MPa: 6.25 atm for 23-mm THVs, 5.5 atm for 26-mm THVs, and 5 atm for 29-mm THVs. Patients within this target range (n = 136) had a 10.0% postdilatation rate, 12.7% mild PVR, and no moderate to severe PVR. The relationship between balloon filling volume and associated pressure and wall stress was inconsistent.Pressure-regulated THV deployment is a simple, reproducible, safe, and effective method, regardless of high-risk anatomical complexities.
- Published
- 2021
50. Health‐related behaviours in a remote Indigenous population with Type 2 diabetes: a Central Australian primary care survey in the Telehealth Eye and Associated Medical Services Network [ <scp>TEAMS</scp> net] project
- Author
-
Anthony C Keech, Alex Brown, D Xu, John Boffa, Kerin O'Dea, Alicia J. Jenkins, Sven-Erik Bursell, Chris Ryan, and Laima Brazionis
- Subjects
Adult ,Male ,Gerontology ,Telemedicine ,Native Hawaiian or Other Pacific Islander ,Alcohol Drinking ,Endocrinology, Diabetes and Metabolism ,Health Behavior ,Population ,Psychological intervention ,030209 endocrinology & metabolism ,Telehealth ,Type 2 diabetes ,Indigenous ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Surveys and Questionnaires ,Internal Medicine ,medicine ,Humans ,030212 general & internal medicine ,education ,Exercise ,Depression (differential diagnoses) ,Aged ,Aged, 80 and over ,education.field_of_study ,Primary Health Care ,Depression ,business.industry ,Smoking ,Australia ,Middle Aged ,medicine.disease ,Diet ,Patient Health Questionnaire ,Diabetes Mellitus, Type 2 ,Female ,business - Abstract
AIM: There is a wealth of data concerning the health behaviours of Indigenous Australians, but the health behaviours of Indigenous Australians with diabetes are not systematically documented. At the clinical level, understanding a person's health behaviours can help identify and address barriers to diabetes care and promote good clinical outcomes. METHODS: We used a novel survey tool to systematically collect health behaviour data on Smoking, Nutrition, Alcohol consumption, Physical activity and Emotional well-being (SNAPE) from Indigenous Australians with Type 2 diabetes in a remote primary care setting in Alice Springs. RESULTS: At least one of the five surveys in the SNAPE tool was completed by 210 participants: 30% male, mean age 52.6 years (range 22.9 - 87.4). Fifty per cent of men and 23% of women were current smokers (P
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.